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5. Abstract

In the stomach, the epithelial stem cells are responsible for glandular homeostasis.
These stem cells continuously undergo cellular proliferation and differentiation to
balance death of senescent cells. Studies conducted on gastric cancers showed
significant increase in parathyroid hormone like hormone (PTHLH). Moreover, both
PTHLH along with parathyroid hormone (PTH) act as endogenous ligands for
parathyroid hormone 1 receptor (PTH1R) which belongs to family B of G- protein
coupled receptors (GPCRs). This receptor functions by mediating many different
signaling pathways and the most studied pathway is the stimulation of cyclic adenosine
mono-phosphate (cAMP) as second messenger.
There are very little studies on understanding the normal function of gastric
PTH1R. Specifically, how PTH1R and its ligands are associated with gastric cancer.
The goal of this project is to investigate the expression of PTH1R in gastric epithelium,
and to understand its possible function and signaling in maintaining gastric
homeostasis. Firstly, gene expression analysis suggested that PTH1R is expressed in
vivo in normal human stomach, and in mouse forestomach, corpus and antrum. In vitro
studies on HeLa, and human embryonic kidney 293 cells (HEK293), also showed
positive expression of PTH1R. However, mouse gastric epithelium progenitor cells
(mGEP) and human gastric cancer cell line (AGS) showed no expression of PTH1R.
To study the mechanism of PTH1R function, transfection of PTH1R plasmid was
successfully conducted in mGEP and AGS cells. Next, we investigated the signaling
pathways activated upon PTH1R stimulation. cAMP assay in transfected AGS cells
treated with PTH1R agonist suggests activation of Gαs signaling pathway. On the other
hand, transfected mGEP cells successfully activated ERK1/2 pathway. Morphological
studies suggested difference in the cell morphology of transfected mGEP cells in
which large cell to cell spaces was reported. Furthermore, cell viability results showed
statistically a non-significant agonist and antagonist trend. Finally, several target genes
were studied by Real-Time PCR. Low density lipoprotein receptor (LDLR) showed
significant upregulation when comparing transfected and activated mGEP cells to
control. However, calcium sensing receptor (CaSR), fibroblast growth factor 23
(FGF23), interleukin-6 (IL-6), and Na+/H+ exchanger regulatory factor 1 (NHERF1)
did not show a significant change. This work highlights the importance of PTH1R in

viii
the stomach which might open new perspectives in studying PTH1R signaling in
gastric cancer patients. This might set new therapeutic modalities for gastric cancer,
especially since PTH1R agonists are used in treatment of bone cancer and
osteoporosis.

Keywords: Parathyroid hormone 1 receptor (PTH1R), parathyroid hormone like
hormone (PTHLH), parathyroid hormone (PTH), gastric epithelium, stem cell.
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)6. Title and Abstract (in Arabic

دور المستقبل  PTH1Rفي توازن الخاليا المعدية
الملخص

خاليا بطانة المعدة هي المسؤولة عن الحفاظ على التوازن في المعدة .وتعد الخاليا
الجذعية الموجودة في المعدة أساسية في تكاثر الخاليا وتمايزها .أظهرت الدراسات التي أجريت
على سرطانات المعدة زيادة كبيرة في هرمون غدة الجار الدرقية مثل هرمون (.)PTHLH
عالوة على ذلك  ،يعمل  PTHLHمع هرمون الغدة الدرقية ( )PTHكجزيئات لمستقبالت
هرمون الغدة الدرقية ( )PTH1Rوالتي تنتمي إلى عائلة  Bمن مستقبالت البروتين (.)GPCRs
يعمل هذا المستقبِل عن طريق التوسط في العديد من مسارات اإلشارات المختلفة  ،والمسار األكثر
دراسة هوالمسار المتعلق بتحفيز مسار  cAMPكرسول ثاني.
هناك القليل من الدراسات حول فهم وظيفة  PTH1Rالطبيعية باللمعدة .على وجه التحديد
 ،كيف ترتبط  PTH1Rبسرطان المعدة .الهدف من هذا المشروع هو بحث تواجد  PTH1Rفي
أنسجة المعدة  ،وفهم الوظيفة الممكنة للمستقبل  PTH1Rفي الحفاظ على التوازن المعدي .يوحي
تحليل التعبير الجيني بإستخدام  PCRوالكيمياء المناعية بأن  PTH1Rيتواجد في أجزاء معدة
الفأر المختلفة .أشارت الدراسات المختبرية على الخاليا المعوية الفأرية ( )mGEPو خاليا
سرطان المعدة البشري ( )AGSإلى عدم تواجد  .PTH1Rللتغلب على هذا التحدي تم إعداد
خاليا  mGEPو  AGSوالمعدلة وراثيا ً لتحتوي على مستقبالت ال , .PTH1Rوبالتالي تم
تنشيط إشارات مسار ال  cAMPفي خاليا ال  AGSو إشارات مسار ال  ERK1/2في خاليا
 .mGEPو بعد ذلك تم قياس بقاء خاليا ال  mGEPعلى قيد الحياة عند تعريض هذه الخاليا
المعدّلة وراثيا ً للهرمون ) PTHrP(1-36أو المثبِت ) .PTHrP(7-34لوحظ زيادة طفيفة في
قدرة الخاليا على البقاء على قيد الحياة بعد  24ساعة من إستخدام ) .PTHrP(1-36كما تم
دراسة تأثير ) PTHrP(1-36على التعبير الجيني لعدد من الجينات مثل LDLR, CaSR, IL-
 .6, NHERF1, FGF23تعد هذه الدراسة مهمة جدا في فهم دور المستقبل  PTH1Rالطبيعي
في المعدة و قد يكون لها تأثير كبير في تطبيقات العالج الكيميائي لمرضى السرطان.
مفاهيم البحث الرئيسية :المستقبالت ,المعدة ,خاليا بطانة المعدة ,الخاليا الجذعية.
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1. Chapter 1: Introduction

1.1 Overview
Receptors in an organism are responsible for different cell responses. These
communication elements are accountable for the cell to cell signal transmission over
short or long distances across the body. Cells are equipped with unique protein
structures located on their surface in order to read out the signals. Such signals lead to
cell responses that can range from minute to major changes inside the cells. Receptors
can be either activated by a specific signal to stimulate them, or can be inhibited by
another signal. The stimulation or inhibition of the receptors can cause multiple
signaling pathways to be activated; as such cells will be able to respond to this
stimulus.
Parathyroid hormone 1 receptor (PTH1R) is a protein receptor found in
multiple tissues of the body, dominantly in the kidney and bones [1,2], but its
significant role in the stomach has not been fully identified [3]. PTH1R is a family B,
G-protein receptor that contains three parts, an extracellular N terminal, seven
transmembrane loops, and intracellular C terminal [2,4]. It has been reported that the
main function of PTH1R is in bones and kidneys where it mediates extracellular Ca2+
homeostasis [3] and is important in bone growth and development [4]. In addition to
these functions, PTH1R has been identified in the intestinal mucosa and in several
carcinomas and adenocarcinomas [3,5].
PTH1R has two ligands, parathyroid hormone like hormone (PTHLH) or also
known as parathyroid hormone related protein (PTHrP), as well as the parathyroid
hormone (PTH). PTHLH is a hormone that plays a key role in bone formation and
growth [6]. It stimulates calcium transport in many tissues, relaxes contracted smooth
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muscles [7], and regulates various cellular events such as proliferation, differentiation
and apoptosis [3]. However, it was also recognized and found to be highly expressed
in hypercalcemia of malignancy, and many other types of cancers such as breast cancer
[3,4,8]. Many studies were conducted and showed increased levels of PTHLH
expression also in thyroid carcinomas [3,9], breast cancer [3], squamous cells tumors
[3,8], and gastric cancers [3]. These studies highlighted the importance of PTHLH
involvement in tumor proliferation and progression [3]. PTHLH is a complex hormone
in which it can function as a paracrine, endocrine, and autocrine hormone [4]. It is well
known that the PTHLH is expressed and found in the stomach [3]; however, very little
research has been done on the expression of PTH1R in the stomach and its role in
maintaining gastric homeostasis. The aim of this thesis is to investigate further the
crucial function of PTH1R in gastric homeostasis.
The focus of this project will be mainly on studying the PTH1R expression and
role in the gastric homeostasis. This will apply further knowledge on the regulation of
this receptor in gastric cancers. To further understand the structure of this project’s
introduction, an overview of detailed stomach anatomy will be discussed first,
followed by G- Protein Coupled Receptors (GPCRs) classification. Then, PTH1R with
insights on its structure, ligands, and signaling pathways will be covered. Furthermore,
PTH1R and its relation to health and multiple diseases associated with stomach, bones,
breast cancer, and kidneys will be explained thoroughly followed by PTH1R mutations
that cause diseases. Lastly, the importance of PTH1R in targeting specific genes and
its relation in regulating system homeostasis will be discussed.

3
1.2 Stomach Anatomy
The stomach of the mouse is composed of three distinct parts, forestomach,
corpus, and the antrum as shown in Figure 1.1. The forestomach is connected to the
esophagus, the middle compartment is the corpus, and the antral distal part which
connects the stomach to the small intestine is called antrum. The forestomach is a nonglandular tissue and is composed of stratified squamous epithelial cells. As for the
corpus and antrum, they are glandular areas. Together, these two areas are responsible
for secreting gastric mucins, hydrochloric acids, digestive enzymes, and hormones.
However, there are differences in the glands between the corpus and the
antrum regions. The organization of these regions and glands is further illustrated in
Figure 1.2. In the corpus, the glands are subdivided into four parts: pit, isthmus, neck,
and base as illustrate in Figure 1.2a.
The isthmus region which contains mainly the progenitor cells, and as a result,
it was noted to contain the highest mitotic activity [10]. The progenitor stem cells also
have the ability to differentiate into other cells which can migrate to the top (pit) of the
gland or in the lower part of the gland (neck or base). The parietal cells found mainly
in the isthmus and neck are the source for gastric acid regulation. They secrete gastric
acid which it plays an important role in food digestion. They can also produce several
growth factors.
The pit, which is the top part of the gland, is an area that contains surface
mucous cells that cover the lining of the stomach and secretes mucus to protect the
stomach from strong acids and enzymes.
Below the isthmus region is the neck region which contains migrated parietal
cells from isthmus, neck region also contains mucous neck cells, and
Enterochromaffin-Like (ECL) endocrine cells which secrete histamine and can
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stimulate parietal cells to secrete gastric acid. Lastly, the base region located at the
very bottom of the gland, containing zymogenic cells which secrete pepsinogen. It is
important to note that the origin of all these cells comes from gastric epithelial
progenitor cells [11-13].
Moreover, the antrum gastric glands consist of surface mucous cells,
progenitor cells, deep mucous cells, G cells which are endocrine cells secreting gastrin,
and Lgr5+ stem cells as shown in details in Figure 1.2b [11,14,15]. The antrum gland
contains highly proliferative regions below the pit region [10]. The gastric stem cells
are responsible for maintaining the epithelial homeostasis inside the gland, due to their
ability to differentiate and proliferate [11].
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Figure 1.1: The mouse stomach anatomy
The mouse stomach is divided into three regions: forestomach, corpus and antrum. The esophagus
connects to the forestomach, while the small intestine connects to the bottom part of the stomach called
antrum. The mid-region of the stomach is called Corpus.

a.

b.

Figure 1.2: Diagram of a gastric gland from corpus (a), and antrum (b)
The corpus gastric gland is further divided into four regions; pit, isthmus, neck, and base. The antral
gland is shorter and consists of Surface Mucous Cells also known as pit, and bottom portion known as
base.
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1.3 G- Protein Coupled Receptors (GPCRs)
GPCRs are the largest proteins in mammals and are categorized into six classes
according to their structural and functional similarities. The six classes are; Class A,
Class B, Class C, Class D, Class E, and Class F [16]. Table 1.1 lists the different
classes, their names, and their biological functions and examples of each class. Class
A named rhodopsin-like which is the largest group among the GPCRs. Class B named
secretin-receptor family, which are regulated by peptide hormones. The Class B
consists of glucagon receptors, parathyroid hormone receptor, and secretin receptors.
Class C includes glutamate receptors and other receptors with similar structure. Class
D, E, and F are important in stimulating multiple signaling pathways and regulate the
activity of many genes [17].
GPCRs share a similar overall structure in which they contain an extracellular
N terminal, seven hydrophobic transmembrane loops, and intracellular C terminal as
shown in Figure 1.3. The N terminal is categorized as a site for ligand binding, while
the seven transmembrane portions consist of alpha helices which alternate within the
lipid bilayer membrane. The intracellular C terminal is bound to G-proteins inside the
cell.
In the last three decades, GPCRs have been of growing interest due to their
powerful actions in several biological events and pharmaceutical drug discoveries.
Previous studies highlight the importance of GPCRs as biomarkers for early cancer
diagnosis [16]. This illustrates the importance of GPCRs signaling target in drug
discoveries, cancer treatments, cellular regulation and signal transduction.
The mechanism of action starts when the ligand binds to the receptor at a
specific active site, this will cause the G-proteins to be activated and induce a
conformational change. This will initiate the activation of series of biochemical
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reactions within the cell. However, the active site in which the ligand binds to the
receptor plays a critical role into which receptor signaling pathway to activate [17].
Upon the activation of GPCR, one of the three subtypes of heterotrimeric Gproteins located inside the cell will be activated, the three subunits are; Gα, Gβ, and
Gγ as illustrated in Figure 1.4. These three subunits can further be classified into
multiple subfamilies, for example Gα is additionally categorized as Gαs, Gαi, Gαq, and
Gα12/13. These subfamilies will cause a cascade of further downstream protein
activations and will therefore trigger a cellular response according to the ligands
stimulus instruction [16].
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Table 1.1: Classification of GPCRs classes and their functions
Class A

Class type
Functions
(Rhodopsin-like) -Important in extracellular
signals.
-Most targeted class in
pharmaceutical industry
[18].

Class B

(Secretin
receptor family)

-Activate adenylyl cyclase
-Important drug targets in
diabetes
-large N-terminal
extracellular domain[19].

Class C

(Metabotropic
glutamate/
pheromone)

-Unique ligand recognition
sites
-Calcium sensing receptors
-Involved in taste and odor
receptors.[20].

Class D

(Fungal mating
pheromone
receptors)

Class E

(Cyclic AMP
receptors)

Class F

(Frizzled/
Smoothened)

Examples
-C-C chemokine
receptor type 1
-Angiotensin II
-Melatonin receptors
[18].
Glucagon-like
peptide 1 GLP-1
-Glucagon
-PTH1R
-Secretin
[19].

-Metabotropic
glutamate receptors
(mGlu)
- γ-aminobutyric acidB
receptors (GABAB)
- Ca2+- sensing
receptors (CaSR) [20].
-Involved in the response to - Pheromone a factor
mating factors on the cell
receptor Ste2, Ste3
membrane[21].
[21].
-Important in regulating
developmental
genes.[22,23].
-Important in cell polarity,
embryonic development,
formation of neural
synapses, and cell
proliferation [24].

- cAMP receptor
subtype ( CAR1,
CAR2, CAR3)[22,23].
- Frizzled receptors
- Smoothened receptor
(SMO) [25].
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1.4 Parathyroid Hormone 1 Receptor (PTH1R)
PTH1R has been categorized as a GPCR which was firstly discovered in 1991
in COS-7 kidney fibroblast like cells [26]. It was detected to be around 80kD in size
and has two ligands PTH and PTHLH. Both of these ligands can bind to PTH1R at
different sites and at different affinities which can activate different GPCR pathways.
PTH1R was classified to be Class B of GPCR due to its high structural similarity to
secretin and glucagon hormone family [3].
Its expression was mostly studied in bones and kidneys due to its important
role in regulating calcium ion homeostasis in the blood through activation of adenylate
cyclase and phospholipase C (PLC). However, PTH1R is also expressed in multiple
other tissues and organs including adrenal glands, placenta, spleen and adipose tissue
[3].
It has been recorded that the genomic location of PTH1R is 3p21.31 in human.
In other terms, it is located on chromosome 3, region 2, band 1, and sub band 31, with
20 exon count. PTH1R mRNA codes for 593 amino acids in human as shown in Figure
1.3, and 591 amino acids for mouse. It is located in chromosome 9 with 21 exon count
in mouse.
Defects and mutations in this receptor can cause Jansen’s Metaphyseal
Chondrodysplasia (JMC) in which bones of the arms and legs tend to develop and
grow abnormally with unusual cartilage and bone formation [2]. Recent studies also
show PTH1R mutations can cause failure of tooth eruption in some human patients
[27]. Defects by PTH1R will be further explained in more details in another section
later in chapter 1 under the title (PTH1R Mutations). However, very little studies
consider studying PTH1R in the gastric system, therefore its role and importance in
gastric homeostasis is not well known to this day.
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1.4.1 PTH1R Structure
Structurally, PTH1R consists of extracellular N terminal, 7 transmembrane
domains, and an intracellular C terminal. As the rest of class B family, PTH1R shares
a sequence homology with other related receptors in this group such as secretin and
glucagon [6]. This identifies that these receptors all share some similarities within their
modes of action and signaling [6].
PTH1R is a receptor that allows for PTH (84 aa) and PTHLH (141 aa) to bind
to it [28]. However, both molecules bind at different affinity and in different regions
of the receptor [28]. On the other hand, PTH1R can be fully activated when small
portions of the ligands bind to it, as such it does not require the full length of the ligand
to completely bind to it [28]. An example is PTH (1-34) which is considered to be an
agonist. It can bind to PTH1R from the N terminal and thus activating the receptor
through Gαs pathway. PTH (1-34) was reported to bind at higher affinity resulting in
prolonged activation and a longer lasting cAMP response of the receptor. Unlike
PTHrP (1-36), which is another agonist, but it was reported to bind at a lower affinity
to the receptor, however, it still activated Gαs pathway [28]. To block the activation
of PTH1R, a peptide used is PTH (7-34) which has been identified to be an antagonist
that inhibits the action of the receptor [28].
Even though the amino acid sequence of PTH1R is identified as illustrated in
Figure 1.3, yet the 3-D protein structure has not been fully established according to
protein data bank (PDB). However, what make PTH1R similar in structure to its other
counterparts in Class B GPCRs is its four pairs of extracellular cysteine (C) specific
amino acids illustrated in Figure 1.3 [29]. These residues can form disulfide bond
which are conserved domain across all Class B [4,29]. This domain allows the receptor
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to maintain its structure and function. Other residues also play an important role in
activating different signaling pathways, for example; Lys388 is important in Gαs
signaling [29].
In the PTH1R intracellular C terminal, a nuclear localization sequence (NLS)
is present, which highlights the regulation of PTH1R localization in the nucleus [30].
Although the transport of GPCRs from the cell membrane into the cell by endocytosis
is well known, the knowledge of transporting GPCRs into the nucleus is relatively
new.
PTH1R was the third GPCR found to indeed translocate to the nucleus of the
cell, which created a new range of studies regarding this phenomena [31]. Studies
demonstrated that PTH1R nuclear import is actually possible [31]. Other studies
confirmed PTH1R nuclear localization in rat liver, kidney, gut, ovary, and uterus [30].
The nuclear localization sequence of PTH1R was identified, which was
reported in the cytoplasmic domain amino acids 471 – 488 of the receptor shown in
Figure 1.3 [30]. It was in fact well documented in another study that PTH1R
translocate to the nucleus when mouse osteoblast-like cells MC3T3-E1 are serum
starved. However, in normal cell culture conditions PTH1R can be found both in
cytoplasm and nucleus [31]. They further studied the mechanism of such action, and
noted that treating the cells with PTH peptide induce PTH1R cytoplasmic localization.
To aid in this mechanism, they reported a relation between Importin α and β, both of
these transport regulatory proteins aid in the translocation of PTH1R to the nucleus.
The Importin protein will interact with the nuclear localization sequence NLS found
in the receptor, this will further cause the translocation of the complex into the nucleus.
To reverse this mechanism, that is, to transport PTH1R from the nucleus back to the
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cytoplasm, chromosomal region maintenance 1 CRM1 protein is involved, this process
is named as nuclear export [31].
The importance of this shuttling can regulate various cellular process, gene
expression and proliferation [31]. However, other studies linked this translocation of
the receptor to happen during DNA synthesis and mitosis. This highlighted the
possible importance of PTH1R during specific stages of the cell cycle [30].

Figure 1.3: Human PTH1R structure
Human PTH1R Amino Acid sequence organization. The composition of different parts and regions of
PTH1R, including N-terminal, seven trans-membrane loops, and C- terminal. Important sequence sites
are: Nuclear localization sequence 471 – 488 highlighted in blue, four pairs of Cysteine highlighted in
red, and Lysine 388 highlighted in green. Modified from [4].
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1.4.2 Ligands
Parathyroid hormone (PTH) is secreted by the parathyroid gland which are four
tiny glands found in the neck. PTH plays a crucial role in maintaining and regulating
calcium ion homeostasis in the blood. When calcium ions in the blood decrease, this
causes the PTH to stimulate bone cells, specifically osteoclasts which help in breaking
down bones to release more calcium in the blood. In other words, PTH can raise
calcium levels by increasing bone resorption which is breaking down of bone tissues
to produce more calcium, as such, this will decrease renal excretion of calcium and
will stimulate Vitamin D to absorb calcium from the intestine through its receptor
VDR [32].
PTH can be regulated via two receptors PTH1R and PTH2R. However, PTH1R
is deeply studied in bones and kidneys. Studies show that PTH treatments can increase
bone mass when intermittently administered at low doses to patients with osteoporosis
[28]. PTH role is very significant in bone regulation and maintain its homeostasis. PTH
knockout mice showed substantial bone deformities and impaired bone formation
[28,33].
Parathyroid hormone like hormone (PTHLH) was discovered as a cancerderived hormone which was reported in humoral hypercalcemia of malignancy
(HHM). The term derives since 1941 [28] when it was first reported as a case study in
a patient with high plasma calcium accompanying a non-parathyroid cancer. During
that time, it was known that excess secretion of PTH causes hyperparathyroidism
which results in high calcium in the blood. However, hypercalcemia was also noted in
other cancers such as lung, breast, and kidney cancers. PTHLH was then identified
through immunochemical cross-reactivity with bovine PTH and immunohistology
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which showed PTH like reactivity. By 1970, scientists concluded that the main cause
of the hypercalcemia, and the tumor derived activity in some cancer patients did not
originate from PTH itself, but from another hormone which very much resembles PTH,
thus Parathyroid Hormone Like Hormone name appeared [34,35]. Recent studies to
this date still support this idea, in which PTHLH is the reason for elevated calcium
levels in blood, as well as tumor derived factor. Moreover, studies also show a similar
N-terminal homology between PTH and PTHLH in the first 13 residues, which
represents a possible agonist for both hormones to act on PTH1R [28].
Both of these ligands have been identified to be mediated through PTH1R.
However, both can bind at different affinity and thus cause different signaling pathway
to be triggered.
Compared to PTH, PTHLH is thought to be produced by many tissues and it is
expressed throughout the gastrointestinal tract [7]. However, very limited number of
studies are conducted involving PTHLH expression in the stomach [36,37], and it
regulatory receptor PTH1R signaling pathway in maintaining gastric homeostasis.
1.4.3 Major PTH1R Signaling Pathways
In the case of PTH1R which is categorized as a GPCR Class B, two ligands
can activate this receptor, PTH and PTHLH. Both of these hormones can further
activate different PTH1R G proteins. The four possible activations are: Gαs, Gαi, Gαq,
and Gα12/13. Figure 1.4 illustrates the multiple types of PTH1R activations. However,
the most studied pathways for PTH1R are Gαs and Gαq [29].
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cAMP signaling pathway
The activation of the Gαs pathway will cause a different cascade of downstream
reactions. Firstly, the activation of adenylyl cyclase (AC), which will generate cyclic
adenosine monophosphate (cAMP). Secondly, cAMP will activate protein kinase A
(PKA) which will regulate several cellular proteins, and target specific genes [6].
To fully activate PTH1R, two highly studied agonists can be used, PTH (1-34)
and PTH (1-36). The N-terminal of these agonists is fully capable of activating the
receptor. Some studies suggest that other agonists like PTH (1-31) can stimulate AC
and PLC pathways, however it cannot internalize PTH1R [38]. On the other hand, PTH
(7-34) acts as an antagonist which causes a blockage or inhibition of PTH1R. Other
peptide activators or inhibitors exist to this day, but they can cause other signaling
pathways in GPCR to be activated. This broad range of peptide activators highlight an
important focus on the specific ligand-receptor binding, which is selective and can
trigger targeted signaling pathways in different organs and cells.
cAMP in the gastric system has important roles in regulating stomach
homeostasis. Parietal cells found in the stomach are responsible in Gastric acid
secretion. These cells contain vesicular tubular organelles that carry a proton pump
H+/K+ ATPase which maintains H+ ion homeostasis in the stomach [39]. It has been
reported that Histamine, gastrin, and acetylcholine act as gastric transmitters.
Histamine is a regulatory hormone responsible to activate Histamine receptor
2 (H2), this receptor is categorized as a GPCR which activates the Gαs signaling
pathway [39]. This activation will initiate Adenylyl cyclase and protein kinase A
which will cause the production of cAMP as a secondary messenger in the cell [40].
Acetylcholine and gastrin are also responsible in the induction of calcium ions.
The intracellular increase in calcium ions triggers parietal cells to produce gastric acid
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[39]. However, these parietal cell transmitters can be activated by different ligands
and can be caused by different stimulus, whether it is increase in calcium ions or
cAMP.
Some studies claim that certain basal levels of cAMP are crucial for the parietal
cells to be stimulated by calcium ions [40]. On the other hand, some studies show that
calcium ions are also important for the parietal cells to be activated through cAMP
pathways [40]. Studies demonstrate a cross talk between calcium ions and cAMP
pathways in general; however more studies are yet to be conducted to verify their
effects on gastric acid secretion [41].

ERK1/2 signaling pathway
One of the highly studied pathways is the phosphorylation of extracellular
signal regulated kinase (ERK1/2). It can be activated by many extracellular signals
such as growth factor and hormones, or it can be activated by GPCR Gα, Gβ, and Gγ.
This pathway is significant in many cellular actions including PTH and PTHLH
involvement in differentiation, proliferation, survival and calcium transport [42].
Activation of this pathway has been reported in many endocrine cells such as;
osteoblasts, bone cells, and kidney cells [42]. Other studies illustrates that activation
of ERK1/2 in stomach cancer cells KATO III through GPCRs induced proliferation
[43]. Some studies even suggested using drugs to inhibit gastric cancer cells from
proliferating via inhibition of ERK1/2 [44]. However, it would be interesting to find
out if PTH1R in the stomach has a role in this activation.
Some studies documented PTHLH amino terminal internalization into the cell
after activating its receptor PTH1R [45]. Moreover, it has also been discovered that
PTHLH contain a nuclear targeting signals located on amino acids 87-107 [45]. It has
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been localized in the nucleus of some skeletal cells in vivo, and its role was significant
in regulating differentiation and apoptosis in vitro [45]. Some studies even proposed
the endocytosis of PTH1R after the ligation with its ligand PTHLH.
Studies investigated the possibility of actually whether or not PTH1R can be
internalized from the cell membrane to the inside of the cell. The entire process of
GPCR desensitization and resensitization is further explained in Figure 1.5. Briefly,
when the ligand binds to the receptor, it will cause the phosphorylation and change in
the conformation of the receptor. This mechanism can cause the uncoupling of Gα,
Gβ, or Gγ subunit from the receptor, this in turn will cause β-arrestin to increase its
affinity to the receptor, and will bind to the receptor causing desensitization. The
receptor will further translocate inside the cell with β-arrestin, in which it can activate
Extracellular signal Regulated Kinases ERK1/2 [38]. Furthermore, the receptor can
either be broken down by lysosomes, or resensitized back to the cell membrane. This
method is helpful in a way which will regulate the receptor activation, and thus prevent
prolonged receptor activity and stimulation [38].
Desensitization of GPCR PTH1R alpha group Gαs and Gαq by β-arrestin was
documented in some studies [38,42]. In a study conducted in 2005, they used human
embryonic kidney (HEK293) cells to investigate PTH1R trafficking and activation of
extracellular signal regulated kinases ERK1/2 by stimulating the receptor with PTH
(1-34) peptide [42]. Consequently, the agonist peptide PTH (1-34) was able to induce
a rapid activation of ERK1/2 in the first five minutes of stimulation unlike in PTH (136), in which they found no similar significant effects. They further proposed that PTH
(1-34) agonist and PTH (7-34) antagonist were able to phosphorylate ERK1/2 and
cause PTH1R internalization into the cell. However, PTH (7-34) antagonist promoted
PTH1R internalization without activation of the receptor. They further suggested that
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PTH1R can actually be internalized into the cell, using the aid of β-arrestin recruitment
to the cell membrane to desensitize the receptor [42].
Another study conducted in 2004 [38], in which they removed a portion of
PTH1R C terminal, and they reported that PTH1R was not able to get internalized into
the cell. They concluded that PTH1R C terminal contain a sequence that is involved
in receptor internalization [38].
The activation of ERK1/2 has been studied intensively in bone marrow cells
and kidney cells, and it is associated with differentiation, proliferation, and calcium
transport. However, very little studies were conducted on stomach to test PTH1R
trafficking into the cell and activating ERK1/2.

PLC signaling pathway
Another pathway for PTH1R is Gαq which will activate phospholipase C
(PLC) which will trigger downstream signaling involving inositol triphosphate (IP3)
and protein kinase C (PKC) [29]. This pathway is further explained in Figure 1.4.
For the purpose of this project, I will be focusing and studying the Gαs pathway
to highlight the importance of cAMP and ERK1/2 generation in gastric cells.
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Figure 1.4: GPCR signaling pathways
GPCR multiple signaling pathways activations and secondary messengers involved in multiple downstream signaling. The focus of this project will be on Gαs and βarrestin ERK1/2 signaling pathway.
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Figure 1.5: GPCR endocytosis trafficking
Detailed explanation of GPCR internalization into the cell by β-arrestin recruitment to the receptor. The diagram illustrates the desensitization and resensitization of
the receptor causing the activation of ERK1/2. Modified from [46].
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1.5 PTH1R in Health and Diseases
In this section PTH1R and its role in different organs and diseases such as in
stomach, bone cancer, breast cancer, and kidneys will be discussed.
1.5.1 PTH1R in Stomach
There is limited number of studies available for PTH1R in the gastric system.
In one family, a case study was conducted in which it linked a mutation of PTH1R and
ATPase H+/K+ to loss of function in parietal cells which lead to gastric tumor,
hypothyroidism and arthritis [47]. Another case study also identified PTHLH and
PTH1R to be highly expressed and involved in gastric tumor and the metastasis of the
tumor to other organs [48]. One study also mentioned the importance of PTH1R in
relaxing gastrointestinal muscles [49]. It is important to note that PTH1R is not well
studied in the gastric system and very limited information is available regarding this
issue. As such, knowledge from other organs and researches will be important in
studying the role of PTH1R in stomach.
1.5.2 PTH1R in Bones
Osteosarcoma (OS) is one of the most common cancer of bones [50]. It occurs
mostly in children, and when diagnosed and localized, patients have a five years
survival rate [50]. However, treatment for osteosarcoma is mainly administered drugs
to control the proliferative cancer cells, or in other cases surgical resection.
PTH plays a major role in regulating bone cells and development of mature
bones. It has been reported that PTH treatments increase bone mass. However, PTHLH
has been reported to play a pivotal role in skeletal development [51].
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Since both of these hormones can act on PTH1R, then this raise a potential on
targeting this receptor to study its importance. It has been reported that intermittent
PTH treatment can increase bone mass and inhibition of osteoblast apoptosis. PTH has
also been reported to be used as a treatment for osteoporosis which enhances bone
resorption [52]. However, long term and high doses of PTH can trigger and cause OS.
This is further supported in other studies [52]. In one study, knockdown of PTH1R
inhibited proliferation and tumor growth inhibition and increased differentiation in
vitro. It is important to note that the knockdown of PTH1R did not affect the viability
of cells in this study, however, it was able to impair the invasion of cells [50]. Other
studies showed overexpression of PTH1R increased proliferation in OS cells
[33,50,54].
Other in vivo studies demonstrated the anabolic bone formation effect of
intermittent low-dose PTH (1-34) treatment on bones [55,56]. However, continuous
high-dose treatment of PTH showed increase in bone turnover, resorption, and
hypercalcemia.
Osteoporosis is defined as an imbalance between bone resorption by
osteoclasts and bone formation by osteoblasts causing reduction in bone mineral
density (BMD) [52]. PTH (1-34) and PTH (1-36) intermittent treatment have been
established as an osteoporosis treatment to induce osteoblastic bone formation and
increasing BMD [28,52,57]. It was also reported in 2002 that PTH (1-34) the first
anabolic agent for treating osteoporosis in the United States [58]. However, due to the
fact that PTH can activate multiple signaling pathways, and not precise exclusive
anabolic actions, another analog PTHLH (1-34) has been recently approved in 2017
for osteoporosis treatment [58].
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1.5.3 PTH1R in Breast Cancer
Breast cancer has been associated previously with skeletal metastases [59].
Some studies suggested a link between breast cancer and PTHLH and considered
breast cancer mediation through PTHLH expression, especially since the identification
of PTHLH in breast cancer in 1987 [59]. It is also important to note that elevated levels
of PTHLH was reported in breast cancer patients and this induced tumor initiation, and
progression, and cellular proliferation [60,58]. Another study reported silencing
PTHLH in breast cancer cells affected over 200 genes expression tested by microarray
analysis [60] .
In another epidemiology study, in which an increase in breast cancer was
associated with type 2 diabetes, they investigated the role of PTH1R on apoptosis of
breast cancer cells exposed to high levels of glucose [61]. It was reported that PTH1R
expression increased in mice with diabetes. Furthermore, they also reported an
increase in PTH1R in patients with breast cancer and diabetes. Additionally, they
found that silencing PTH1R inhibited cell proliferation and promoted cell apoptosis
induced by high levels of glucose [61].
Moreover, breast cancer patients have reported severe bone pain and
hypercalcemia, which eventually lead to skeletal metastasis [58,60]. It is known that
PTH1R regulate calcium homeostasis along with extracellular calcium-sensing
receptor (CaSR). This highlights the important cross talk between breast cancer and
bone cells by PTH1R. It was also proposed a future targeting of PTH1R and CaSR in
order to control breast cancer tumor growth and inhibition on cell proliferation as well
as the metastasis to the skeleton [58].
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1.5.4 PTH1R in Kidneys
PTH1R has been reported to be highly expressed in the kidney for its effective
role in maintaining its development maturation, structure and function by regulating
calcium ions in the blood [62].
Calcium homeostasis in the blood plays a crucial role in kidneys. When the
calcium level is low, this stimulates the chief cells in the parathyroid glands, and thus
PTH secretion will increase and will allow it to bind to PTH1R. Furthermore, this will
help in renal tubular reabsorption of calcium and in fact will increase Vitamin D
synthesis to induce calcium absorption in the gut and hence facilitate osteoclast bone
resorption to secrete calcium ions. In this mechanism, the body will be able to maintain
systemic mineral ion homeostasis and calcium levels in the blood [63].
In a diabetic kidney, it was shown that PTHLH and PTH1R are overexpressed.
It was reported that treating renal kidney cells with high glucose will increase the
expression of PTHLH and PTH1R [1].
In one study on human embryonic kidney cells, they activated PTH1R and
tested the apoptotic signaling pathways effects. They reported that PTH1R activated
mitochondrial apoptosis pathways, and the overexpression of PTH1R led to an
imbalance in the mitochondrial membrane. This highlighted the importance of PTH1R
in apoptosis of kidney cells [64].
PTHLH and PTH1R have been under the investigation for their upregulation
in renal injuries [65]. This, in fact, will cause the development of renal hypertrophy
and diabetes. This in turn will cause an imbalance in the mineral ion homeostasis [65].
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1.6 PTH1R Mutations
Mutations in PTH1R have been reported to be associated with multiple
diseases such as; Jansen type metaphyseal chondrodysplasia, primary failure of tooth
eruption, and Eiken skeletal dysplasia according to online Mendelian inheritance in
man database (OMIM).
Jansen type metaphyseal chondrodysplasia is a mutation categorized as a
heterozygous missense mutation in PTH1R gene in which it is categorized by short
limbed dwarfism caused by impaired growth plates of bones and mineral ion
imbalance. The mutation is thought to be in amino acids residue 223 in which Histidine
was replaced with Arginine [2,66,67].
Primary failure of tooth eruption is a heterozygous splice site or nonsense
mutation in PTH1R [62]. This disease is categorized as growth deficiency in teeth [27].
The mutation is reported in multiple places, for example it is noted in amino acid
position 155, in which Glutamate undergoes Termination [68].
Eiken skeletal dysplasia is another bone disorder is which abnormal modeling
of the bones and cartilage and severely delayed ossification is found in the hands, feet,
and pelvis [48]. It is reported as a homozygous nonsense mutation in the c-terminal of
PTH1R gene. Moreover, the specific truncation of the mutation on Arginine 485 to
Termination [69]. This disorder is very similar to Jansen type metaphyseal
chondrodysplasia, however, an important finding in one study in which they compared
both disorders found that there was significant increase in vitamin D in patients with
Jansen type metaphyseal chondrodysplasia [70] compared to Eiken patients [69].
However, no further discussion was related to highlight this issue.
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1.7 PTH1R Target Genes
PTH1R is involved in several cross talks with other receptors. The activation
or inhibition of PTH1R is involved in multiple regulatory actions downstream in the
genomic pathway. Examples of some PTH1R direct and indirect target genes include:
calcium sensing receptor (CaSR), fibroblast growth factor 23 (FGF23), interleukin-6
(IL-6), low density lipoprotein receptor (LDLR), and Na+/H+ exchanger regulatory
factor 1 (NHERF1) as shown in Table 1.2.
The extracellular calcium sensing receptor, also known as CaSR, is a family C
GPCR. Its major role is to detect minor alterations in blood calcium levels, and in turn
indirectly induce PTH secretion and urinary calcium excretion [71]. Regulating
calcium is a very complex process that involves many components to maintain its
homeostasis. When calcium levels in the blood drops, this is sensed by CaSR, which
in turn stimulates the parathyroid gland to secret PTH. This hormone will stimulate
PTH1R to induce bone resorption which breaks down the bones to release calcium
ions into the blood. Furthermore, PTH will also enhance Vitamin D synthesis in the
renal system which will aid the intestines in calcium absorption [71-74]. This
regulation mediates calcium homeostasis, and as such leads to feedback inhibition of
PTH secretion.
The cross talk between CaSR and PTH1R has been reported previously in
breast cancer [75]. PTHLH has been involved in breast cancer tumor progression and
metastasis to the bones. It is reported that CaSR contributes to breast cancer cell
proliferation [58].
CaSR was also found to be expressed in gastric tissues in parietal cells [76],
and in gastric cancer. Studies illustrate the upregulation of CaSR expression [77]. For
many years, calcium supplements were used as treatment for gastric cancer. However,
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it has been reported that calcium activates CaSR and causes gastric cancer growth,
unlike the case in colorectal and pancreatic cancer, in which calcium suppressed the
tumor growth [77].
FGF23 has been reported to be induced and upregulated directly by PTH in
bones when there is high phosphate and vitamin D levels in the blood [78,79]. Other
studies demonstrated that PTH (1-34) treatment in vitro to osteocyte-like cells resulted
in increased levels of FGF23 in the first initial 2 hrs, but the levels returned back to
normal by 4 hrs. [80] Another study conducted in which PTH1R was deleted from
kidney in mice showed significant increase in FGF23 and challenging the mice with
PTH (1-34) caused an upregulation of FGF23 [81]. However, removal of PTH1R from
bones downregulated FGF23 levels [81].
IL-6 is a pro-inflammatory cytokine studied in cases of hyperparathyroidism
in which it is indirectly upregulated when PTHLH stimulates PTH1R in cancer cells
[83]. IL-6 has been studies in patients with gastric cancer, and research shows that IL6 is involved in gastric cancer spread of tumor and invasion [84,85]. Another study
related PTH treatment in osteoblastic cells and results showed an induction in IL-6
[5,86,87].
LDLR is responsible for the uptake of cholesterol and is very important in
maintaining plasma levels of lipoprotein. PTH is shown to induce LDLR when it binds
to PTH1R [88]. Very limited number of research that related PTH1R and LDLR
especially in gastric system.
NHERF1 consists of two domains, PDZ and carboxyl-terminal ezrin binding
domain (EB). NHERF1 acts as cytoplasmic adaptor protein and has the ability to bind
and form different complexes with other molecules causing trafficking [89]. It is also
involved in cancer progression such as in breast cancer and gastric cancer [90], and is
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important in cellular localization [91,92]. NHERF1 levels were detected at high
amount in nucleus of cancer cells, thus altering some signaling pathways and second
messengers [92]. NHERF1 has been documented to directly interact with PTH1R and
internalize with it when it is desensitized and cause endocytosis of the receptor into
the cell [92,93,95].
1.8 Thesis Objectives and Hypothesis
Since there are limited studies focusing on PTH1R importance in the stomach,
this project will investigate this issue further. This study is important as it will explore
the expression and function of PTH1R in the stomach, and how this receptor signaling
affects gastric homeostasis. This work might also set some impacts in the development
of new therapeutic agents for gastric cancers.
There are two goals of my master thesis; the first is to find the expression and
cellular localization of PTH1R in the mouse stomach, second, is to study the role of
PTH1R signaling in gastric epithelial homeostasis in vitro.
Moreover, I am hypothesizing that PTH1R is expressed in the mouse stomach
and its signaling is required for gastric epithelial homeostasis. To support my
hypothesis, different experiments will be conducted involving PCR, Immunostaining,
and western blot.

29
Table 1.2: Some PTH1R target genes
Target Gene

Function

Reference

CaSR

Calcium Sensing
Receptor

To detect minor
alterations in blood
calcium levels.

[71,72]

FGF23

Fibroblast Growth
Factor 23

Is a bone derived
hormone regulating
vitamin D activation in
kidney.

[78,79]

IL-6

Interleukin-6

A pro-inflammatory
cytokine which is
studied in cases of
hyperparathyroidism.

[83]

LDLR

Low Density
Lipoprotein Receptor

[88]

NHERF1

Na+/H+ Exchanger
Regulatory Factor 1

Responsible for the
uptake of cholesterol
and is very important in
maintaining plasma
levels of lipoprotein.
Acts as cytoplasmic
adaptor protein and has
the ability to bind and
form different
complexes with other
molecules causing
trafficking.

[79,80]
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2. Chapter 2: Methods

2.1 Animals and Cells
C57BL/6J three month old mice (n=3) (2 males, 1 female) were kept in Specific
Pathogen Free (SPF) facility located in the Faculty of Medicine and Health Sciences
in United Arab Emirates University (UAEU). The mice were fed normal diet
D10012Gi, Research Diet for three months, and then starved over night before
dissection. Stomach tissue was collected to conduct IHC and Real-Time PCR analysis.
Cells used were Gastric Adenocarcinoma (AGS), stomach cancer cells NCIN87, cervical cancer cells HeLa, cells obtained from American Type Culture
Collection (ATCC), Human Embryonic Kidney (HEK293) generously provided by Dr.
Ayoub (UAEU), and Mouse Gastric Epithelium Progenitor cells (mGEP) which are
cells derived from FVB/N transgenic mouse expressing an oncogene, the simian virus
(SV40) large T antigen gene [96] were generously provided by Dr. Karam (UAEU).
mGEP and AGS cells were cultured in RPMI-1640 medium (Sigma), and HEK293
cells were cultured in DMEM medium (Gibco). Both mediums were supplemented
with 10% Fetal Bovine Serum (FBS) and 100 U/ml/50μg/ml Penicillin-Streptomycin
(Life Technologies). Cells were grown in a humidified Binder incubator at 37°C in 5%
CO2 atmosphere.
2.2 RNA Isolation and Reverse-Transcription PCR
For the mice stomach, total RNA was isolated from different stomach regions
(forestomach, corpus, and antrum) using RNeasy Mini Kit (Qiagen). Normal human
stomach total RNA sample was purchased from Origene. RNA isolation for the cells
was also using RNeasy Mini Kit. RNA clean-up was also conducted using RNase-Free
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DNase Kit (Qiagen). cDNA was then synthesized using iScript cDNA synthesis Kit
(Bio-Rad) by using 1μg of RNA as recommended by the manufacturer.
RT-PCR was used to test the expression of PTH1R and other genes in vivo and
in vitro by using GoTaq Flexi DNA Polymerase kit (Promega). Primers and product
size used are listed in Table 2.1.
PCR product was then separated by gel electrophoresis using 1.5% agarose gel
with Ethidium Bromide and bands were visualized using Gel Doc EZ Imager (biorad).
2.3 Histological analysis
Mouse gastric tissue collected was fixed by Bouin Fixative for 24 hrs., then
washed with 70% ethanol and processed by using 5μm sections. Slides were then
stained with the appropriate antibody and imaged using Olympus microscope IX83.
2.3.1 Immunohistochemistry (IHC)
Immuno-peroxidase staining was used by heat induced antigen retrieval, and
all sections were pretreated with 3% H2O2 to inhibit endogenous peroxidase activity.
Sections were incubated with 1% Bovine Serum Albumin for one hr. Followed by
overnight 4°C staining with Rabbit Polyclonal to anti Parathyroid Hormone Receptor
1 (ab75150, abcam, dilution 1:100). Then, biotin-SP conjugated goat anti-rabbit was
used and incubated for one hr. at room temperature. Followed by PBS wash, slides
were then incubated with Extravidin-Peroxidase at dilution 1:1000 in blocking reagent
at room temperature. Further PBS washing, and then DAB:UREA (1:1) was added for
six minutes and washed with distilled water and counterstained with hematoxylin.
Lastly, slides were dehydrated and then mountain DPX was used.
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2.3.2 Immunocytochemistry (ICC)
mGEP and AGS cells were stained and imaged using Olympus microscope
IX83. Cells were seeded on 6 well plate with coverslip inserted at a density of 200,000
cells/well using RPMI-1640 Full medium. Cells were then transfected and left till 70%
confluent. Cells were rinsed with PBS and fixed with 3% Formaldehyde in 1xPBS for
20 minutes at room temperature, followed by PBS rinsing. Cells were then
permeabilized using 0.1% triton x 100 PBS for 15 minutes at room temperature,
following with PBS rinsing. Cells were blocked with 1% Bovine Serum Albumin
(BSA) for one hr. at room temperature. Cells were incubated with primary antibody
Rabbit Polyclonal to anti Parathyroid Hormone Receptor 1 (ab75150, abcam, dilution
1:50) in blocking reagent overnight. Next day, cells were rinsed by PBS containing
1% goat serum for 10 minutes and incubated with secondary antibody goat anti-rabbit
IgG H&L Cy3 (ab6939) for one hr. at room temperature followed by PBS washing.
Finally, DAPI with mounting media was placed on the microscopic slide and the
coverslip was placed on top. Negative controls were used in the absence of primary
antibody.
2.4 Transformation and Transfection
Two PTH1R dry plasmids were purchased from (cDNA Resource Center)
weighing 5000ng, clone ID PTHR100000 and PTHR10TN00. Autoclaved water (50
μL) was added to each tube, 100ng/μL concentrations of the plasmids were used
further for transformation. Plasmids were placed in 37°C water bath for 10 minutes.
Bacteria cells were used NEB 5-alpha competent E. coli. Plasmids and bacteria
were mixed and placed 10 minutes on ice, followed by 45 seconds at 42°C in heating
block, then five minutes on ice. 500 μL of SOC LB media was placed with each
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plasmid and incubated for one hr. at 37°C shaking incubator. Next, tubes containing
plasmids and bacteria were centrifuged at 5000 rpm for five minutes. Supernatant was
removed, and the pellet was re-suspended in LB media. Mixture was plated on Agar
petri-dish containing Soya, Bacteriological Agar, Kanamycin, and Ampicillin and left
to dry for 10 minutes. Petri-dishes were then incubated at 37°C inverted for 24 hrs.
until bacteria colonies are visible.
Next, 200 ml SOC LB media is prepared with 200μL of ampicillin and placed
in a flask. One colony from the grown bacteria is taken using a tip and placed inside
the flask and incubated at 37°C overnight in shaking incubator. Next day, samples
were centrifuged at 6000g for 15 minutes. Supernatant was discarded, and the pellet
was stored in -20°C.
For plasmid extraction and purification Qiagen Plasmid Maxi Kit was used as
recommended by the manufacturer. Concentrations of the plasmids were further
checked by NanoDrop 2000 from Thermo Scientific. Plasmids were diluted to make
the concentration up to 1μg/μl. Gel electrophoresis was used to check DNA integrity
using 1% gel.
For transfection, lipofectamin 2000 from (Invitrogen) and Opti-MEM reduced
serum media from (Gibco) were used. When transfecting 6 well plate, cells need to be
seeded until 70% confluent. Next, two complexes were made. First, 12μg of plasmid
is diluted in 1,200μL OpTi-MEM, and second is 50μL lipofectamin is diluted in
1,200μL Opti-MEM. Solutions are incubated at room temperature for 5 minutes, then
mixed together and incubated for 30 minutes at room temperature. Old media is
discarded from the 6-well plate cells and new fresh media is added with the
transfection-plasmid mix. Cells were kept for 24 hrs, then starved overnight and then
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treated with different doses of agonist PTHrp (1-36) and antagonist PTHrp (7-34)
(Bachem).
2.5 Western Blot
mGEP cells were cultured in 6 well plate at a density of 200,000 cells/well
using RPMI-1640 medium supplemented with 10% FBS and 100U/ml/50μg/ml
penicillin-streptomycin. Cells were transfected with PTH1R plasmid 2μg/well for 24
hrs, and then starved overnight for 12 hrs before introducing the agonist PTHrP (1-36)
at 0.01μM and 0.1μM concentrations for 5 minutes. Cells were lysed using RIPA
buffer containing phosphatase and protease inhibitors. Cells were incubated for one
hr. at 4°C and then scrapped and centrifuged and the supernatant containing the protein
was collected.
Resolving/separating gel 10% and 5% stacking gels, containing H2O, 40%
Acrylamide, 1.5M Tris (pH 8.8), 10% sodium dodecyl sulfate (SDS), 10% Ammonium
Persulfate (APS), and Tetramethylethylenediamine (TEMED) were prepared.
Proteins were then transferred from the gel to the Polyvinylidene difluoride
(PVDF) membrane for 90 minutes at 100 Volts, followed by blocking using 5%
skimmed milk. ERK1/2 and pERK1/2 antibody from (cell signaling technology) were
used at dilutions 1:1000 in 5% BSA, and 1:2000 in 5% skimmed milk respectively.
Membranes were incubated at 4°C overnight. Membranes were then incubated with
cell signaling technology secondary antibody anti-rabbit for ERK1/2 and anti-mouse
for pERK1/2 for 45 minutes. SuperSignal™ ELISA Femto Substrate from
(ThermoFisher Scientific) was used as substrate. Bands were detected using BioRad
Universal Hood II Gel Doc System.
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2.6 cAMP Measurement
cAMP measurement was done by two different kits. cAMP-Glo Max Assay
obtained from Promega, and cAMP-Gs dynamic kit from CisBio.
For the Promega-cAMP, kit, AGS cells were seeded and transfected in 96 well
plate. Preparation of the reagents including induction buffer, detection buffer and
kinase reagent were prepared according to the manufacturer’s instructions. Reagents
were added to the treated cells, and plate was read using plate reader- Glomax from
Promega.
Cisbio-cAMP kit was also used to detect levels of cAMP after treating the cells
with agonist. Cells were seeded and transfected, stimulation buffer, Anti-cAMP
cryptate (donor) was added along with cAMP d2 (acceptor) and incubated for 25
minutes at 37°C before reading the plate using TriStar2 S LB 942 from Berthold
Technologies. All reagents were prepared according the manufacturer’s instructions.
2.7 Cell Morphology Analysis
mGEP cells were cultured in 6 well plate at a density of 200,000 cells/well
using RPMI-1640 medium supplemented with 10% FBS and 100U/ml/50μg/ml
penicillin-streptomycin. Cells were transfected with PTH1R plasmid 2ug/well for 24
hrs., and then starved overnight for 12 hrs. before introducing the treatment at different
concentration. Agonist PTHrP (1-36) and antagonist PTHrP (7-34) concentrations
were 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and 10 μM. Treated cells morphological
changes were monitored at different times (6, 12, 24, and 48 hrs). Imaging was done
using Olympus microscope IX83. Experiment was conducted in triplicates.
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2.7.1 Cell Cytotoxicity
mGEP cells were seeded in triplicate in 96-well plate at a density of 5,000
cells/well using regular RPMI-1640 medium supplemented with 10% FBS and
100U/ml/50μg/ml penicillin-streptomycin. Cells were transfected with PTH1R
plasmid for 24 hrs., cells were then starved overnight for 12 hrs. with serum free media.
Cells were then treated with different concentration of agonist PTHrP (1-36) and
antagonist PTHrP (7-34). Concentrations were 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and
10 μM. Reading were taken after 24 hrs, and 48 hrs. Controls used were Un-transfected
cells and transfected cells not treated. The effect of the drugs on cell viability was
determined using Cell Cytotoxicity Kit (Abcam 112118) according to the
manufacturer’s instructions. Experiment was conducted four times.
2.8 Quantitative Real-Time PCR
QRT-PCR QuantiStudio 5 (Applied Biosystems(ABI)) was used to determine
the effect of transfected mGEP cells treated with (1μM) PTHrP (1-36) on different
target genes. SYBR green dye was used for quantification of cDNA. Table 2.2 shows
the different target gene primers used for the reaction. PCR reaction volume of 20μl
were used for 40 amplification cycles. Samples were loaded in triplicates and values
were calculated using ΔΔCT Method and normalized to GAPDH gene expression
level.
2.9 Statistical Analysis
Statistical analysis was conducted using Graphpad Prism 7.0.3 in order to
calculate the significance and draw the graphs. Data analyzed via one-way or two-way
ANOVA test, while comparing the data as means +/- SD followed by Dunnett’s
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multiple comparisons post-test. Significance was indicated using asterisks *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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Table 2.1: Oligonucleotides primers for the studied target genes
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Figure 2.1: Experimental design of the project
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3. Chapter 3: Results

3.1 PTH1R is Expressed in Human Stomach and Cell Lines
RNA analysis for normal human stomach, and multiple human cell lines such
as HeLa and HEK293 showed positive gene expression of PTH1R using PCR.
However, AGS, and NCI-N87 which are two cancer stomach cell lines did not
indicate an expression for PTH1R as shown in Figure 3.1.

PTH1R
GAPDH
Figure 3.1: PTH1R mRNA is expressed in human stomach and other human cell
lines
RT-PCR detected expression of PTH1R in normal human stomach, HeLa cells which are derived from
cervical cancer, HEK293 which are Human Embryonic Kidney cells. No expression for PTH1R was
detected in AGS and NCI-N87 which are two stomach cancer cells.
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3.2 PTH1R is Expressed in Normal Mouse Gastric Epithelial Tissues
RNA analysis using normal mouse stomach three distinct regions
(forestomach, corpus, and antrum) showed positive gene expression of PTH1R.
However, mGEP cells did not show any expression using PCR Figure 3.2 (A).
To further confirm this result at the protein level, IHC was conducted on the
corpus gland of wild type mouse. Staining results showed a positive expression of
PTH1R in the base of the corpus gland. Kidney tissue was used as positive control.
PTHLH gene expression was detected in mGEP cells as shown in Figure 3.2 (B).

A

PTH1R
GAPDH

B

Figure 3.2: PTH1R gene is expressed in gastric tissue of wild type mouse
(A) RT-PCR detected expression of PTH1R gene in gastric epithelial tissue of C57BL/6J wild type mice
(n=3) at the age of 3 months. The tissues were collected from different regions of the stomach tissue
(Forestomach, Corpus, and Antrum). (B) RT-PCR detected expression of PTHLH gene in mGEP cells.
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Figure 3.3: Immunohistochemical analysis of the corpus gastric gland showing
PTH1R expression
Wild type C57BL/6J mice (n=3), (age 3 months) were sacrificed and the collection of stomach and
kidney was done. (A and B) represent sections in mouse Corpus tissue. (C and D) represent mouse
kidney sections. The staining for PTH1R was conducted using Rabbit polyclonal to anti-Parathyroid
Hormone Receptor 1 (dilution 1:150) and biotin-SP conjugated goat anti-rabbit IgG (H+L). Scale bar:
200μm.
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3.3 The Transfection of mGEP and AGS Cell Lines with PTH1R Plasmid
To overcome the limitation that PTH1R was not expressed in stomach cell lines
mGEP and AGS. Transient transfection of PTH1R plasmid was conducted to force an
expression of the target receptor PTH1R by the cells. To confirm that PTH1R plasmid
was successfully transfected into mGEP (Figure 3.4) and AGS cells (Figure 3.5),
Immunocytochemistry was conducted. It was noted the cellular localization of PTH1R
to be expressed in both nuclear and cytoplasmic in mGEP and AGS cell lines.

UT-mGEP

T-mGEP

Control

Figure 3.4: mGEP cells expressing PTH1R after successful transfection
(A, B, C) represents un-transfected mGEP. (D, E, F) represents PTH1R transfected in mGEP. (G, H, I)
represents mouse kidney as the control. Staining was done using Rabbit Polyclonal to anti Parathyroid
Hormone Receptor 1 (ab75150, abcam, dilution 1:100). Scale bar (A to F) is 100μm. Scale bar (G to I)
is 200μm.
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UT-AGS

T-AGS

Control

Figure 3.5: AGS cells expressing PTH1R after transfection
(A, B, C) represents un-transfected AGS cells. (D, E, F) represents PTH1R transfected in AGS. (G, H,
I) represents mouse kidney section as positive control. Staining was done using Rabbit Polyclonal to
anti Parathyroid Hormone Receptor 1 (ab75150, abcam, dilution 1:100). Scale bar (A to F) is 100μm.
Scale bar (G to I) is 500μm.
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3.4 The Induction of cAMP in Transfected AGS Treated with PTH1R Agonist
Suggests Receptor Activation via Gαs Signaling Pathway
To study the effect of PTH1R agonist PTHrP (1-36) in gastric cells; AGS cells
Dunnett's multiple comparisons test
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cAMP increased after treating the cells with PTHrP (1-36) as shown in Figure 3.6.

c A M P P r o d u c t io n

( % o f F o r s k o l i n i n A G S c e l ls )

B asal
F o r s k o lin (1 0 u M )
125

P T H rP (1 -3 6 ) (1 u M )

****

****

****

100

75

50

25

0
AG S

AG S + P T H 1 R

T r a n s f e c t io n s

Figure 3.6: cAMP induction in PTH1R transfected AGS cells
AGS cells were transfected and treated with PTHrP (1-36) agonist 1μM. Forskolin 10μM was used to
stimulate the production of cAMP as a positive control. Data represents positive stimulation of cAMP
after treating transfected AGS with PTHrP agonist. Two-way ANOVA test was used for data analysis.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3.5 No Induction of cAMP in Transfected mGEP Cells after PTHrP (1-36)
Treatment
Since there was a positive induction of cAMP after treating the transfected
AGS cells with agonist PTHrP (1-36), we tried investigating if mGEP cell line will
be able to induce cAMP and activate Gαs pathway thus having similar effect on
signaling pathway like AGS cell line. There was no induction of cAMP in PTHrP (136) treated and transfected mGEP cells, unlike AGS cells. Results show a positive
cAMP response to Forskolin, but not to PTHrP (1-36) shown in Figure 3.7.

Figure 3.7: No cAMP induction in PTH1R transfected mGEP cells
mGEP cells were transfected and treated with PTHrP (1-36) agonist 1μM. Forskolin 10μM was used to
stimulate the production of cAMP as a positive control. Data represents no stimulation of cAMP after
treating transfected mGEP cells with PTHrP agonist. Two-way ANOVA test was used for data analysis.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3.6 PTHrP (1-36) Caused Phosphorylation of ERK 1/2 in Transfected mGEP
Cells
Transfected mGEP cells did not show any response in activating the Gαs
signaling pathway by the induction of cAMP after PTHrP (1-36) treatment. Another
possibility was to test the activation and phosphorylation of ERK pathway after
treating the transfected mGEP cells with PTHrP (1-36). Transfected mGEP cells were
treated with different concentrations of PTHrP (1-36) agonist for five minutes.
Concentrations used (0.01 μM and 0.1 μM). Results indicate a rapid activation and
phosphorylation of ERK1/2 in transfected mGEP cells as shown in Figure 3.8.
Phosphorylated ERK1/2 was compared to total ERK1/2 and the fold increase
was calculated. Results indicate 22 fold increase of phosphorylated ERK1/2 compared
to the total ERK1/2 in the transfected mGEP treated with 0.01μM PTHrP (1-36) for
five minutes. Furthermore, results showed significant 36 fold increase of
phosphorylated ERK1/2 compared to Total ERK1/2 in the transfected mGEP treated
with 0.1μM PTHrP (1-36) for five minutes.
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ERK fold increase of T-mGEP vs. UT-mGEP
treated with PTHrP(1-36)
40

Fold increase
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15

T-mGEP
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(0.01 μM)

(0.1 μM)
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Figure 3.8: The activation of ERK1/2 pathway in PTH1R transfected mGEP
mGEP cells were transiently transfected for 48 hrs with PTH1R (2μg/well). Serum starved cells were
treated with PTHrP (1-36) at two different doses (0.01 μM) and (0.1 μM) for five minutes before lysis.
Bar graph represents the fold increase of pERK1/2 compared to Total ERK1/2. Highest fold increase
was reported at concentration 0.1μM after PTHrP (1-36) treatment.
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3.7 Effect of PTHrP (1-36) and PTHrP (7-34) on Transfected mGEP Cell Viability
The effect of different concentrations of PTHrP (1-36) and PTHrP (7-34) at
different times was tested on PTH1R transfected mGEP cell line shown in Figure 3.9.
Concentrations varied from 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2.5, 5, and 10 μM. Although
repeated several times, the results demonstrated inconsistency among the groups of
each treatment (experiment repeated at least three times for both time points). There
was a trend with slight increase after treatment with agonist at 24 hrs. However, this
change is not significant.
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A

B

Figure 3.9: Cellular viability of PTH1R transfected mGEP upon agonist and
antagonist treatment for 24 and 48 hrs
PTHrP (1-36) and PTHrP (7-34) did not show any consistent significance or results recorder at 24 hrs.
and 48 hrs. Statistical analysis for cell viability data was performed using Two-way ANOVA test.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3.8 Morphological Changes in mGEP Cells Treated with PTHrP (1-36) and
PTHrP (7-34)
Morphological observations of mGEP cells treated with PTHrP (1-36) as
shown from (Figure 3.10 to Figure 3.13) and PTHrP (7-34) as shown from (Figure
3.14 to Figure 3.17) for different times (6, 12, 24, and 48 hrs.) and different doses
(0.01, 0.1, 0.2, 0.5, and 1 μM). Results show change in shape and structure between
untransfected and transfected cells in different conditions. Different doses of each
treatment did not show drastic morphological changes except for long connections and
cell membranes connecting one cell to another. Rounding and shrinking of cells were
observed in all treatments at different doses.
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PTHrP (1-36) treatment (6 hrs.)

Figure 3.10: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 6 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (1-36) treatment for the first 6
hrs.
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PTHrP (1-36) treatment (12 hrs.)
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Figure 3.11: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 12 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (1-36) treatment for 12 hrs.
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PTHrP (1-36) treatment (24 hrs.)

Figure 3.12: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 24 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (1-36) treatment for 24 hrs.
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PTHrP (1-36) treatment (48 hrs.)

Figure 3.13: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (1-36) after 48 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (1-36) treatment for 48 hrs.
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PTHrP (7-34) treatment (6 hrs.)

Figure 3.14: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 6 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (7-34) treatment for 6 hrs.
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PTHrP (7-34) treatment (12 hrs.)

Figure 3.15: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 12 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (7-34) treatment for 12 hrs.
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PTHrP (7-34) treatment (24 hrs.)

Figure 3.16: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 24 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (7-34) treatment for 24 hrs.
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PTHrP (7-34) treatment (48 hrs.)

Figure 3.17: Morphology of UT-mGEP and T-mGEP cells treated with PTHrP (7-34) after 48 hrs
The observed morphology of T-mGEP cells showed larger spaces between cells and clustering at different concentrations of PTHrP (7-34) treatment for 48 hrs.
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3.9 Expression of PTH1R Target Genes after PTHrP (1-36) Treatment
Expression of PTH1R target genes were examined using Real Time-PCR after
transfecting mGEP cells for 24 hrs., starved overnight, and then treated with PTHrP
(1-36) for five minutes before extracting the RNA. The control cells used were
transfected cells not treated with PTHrP (1-36).
In the case for CaSR, FGF23, IL-6, and NHERF1, while comparing transfected
mGEP to transfected and treated mGEP with PTHrP (1-36), there is no significance
change in the gene expression. However, for the target gene LDLR, there was
significant increase in transfected and treated mGEP cells in comparison with
transfected mGEP cells.
On the other hand, while comparing untransfected mGEP to transfected mGEP,
there was a significant reduction of gene expression in CaSR, FGF23, IL-6, and
NHERF1 in transfected mGEP. However, LDLR gene expression was upregulated in
transfected mGEP in comparison to untransfected mGEP (Figure 3.18).
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Figure 3.18: Relative mRNA expression of PTH1R target genes in mGEP cells
RNA expression of PTH1R target genes was analyzed by Real Time-PCR in Untransfected mGEP, Transfected mGEP, Transfected and treated mGEP with PTHrP
(1-36) for five minutes. Results were compared to the control which is Transfected mGEP. One-way ANOVA test was used for data analysis. *p<0.05, **p<0.01,
***p<0.001,****p<0.0001.
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4. Chapter 4: Discussion

PTH1R regulates calcium ion homeostasis in bones and kidneys, as supported
by many extensive researches [29]. However, very limited studies focused on other
regulatory and functional effects of PTH1R in the gastric system.
In the present study, the expression of PTH1R in gastric epithelial cells both in
vivo and in vitro was examined. Even though the expression was detected in normal
human and mouse stomach as shown in Figure 3.1 and 3.2 respectively, the expression
was not detected in cell lines representative of mouse gastric progenitor cells, and
human gastric cancer cells.
The absence of PTH1R expression in cells was managed by transfecting
PTH1R into the cells. To confirm successful transfection, the cells were stained against
PTH1R antibody, and the localization of the receptor was detected to be cytoplasmic
and nuclear as shown in Figure 3.4 and Figure 3.5. Although PTH1R is a GPCR, which
consists of large sequence of amino acids for its protein structure embedded in the cell
membrane, yet studies reported its ability to localize into the cytoplasm and nucleus
via its NLS which is shown in the diagram Figure 1.3, this is consistent with other
studies [30,31] .
PTH1R acts on multiple signaling pathways when it is stimulated [29]. In our
study, we found that the human gastric cancer cell line activated Gαs as shown in
Figure 3.6. However, mouse gastric progenitor cells failed to induce Gαs Figure 3.7,
and as such another signaling pathway was examined, and we confirmed the activation
of ERK1/2 as shown in Figure 3.8. ERK1/2 is a known pathway for many endocrine
cells and its importance in various cellular processes including proliferation has been
documented in a number of studies [42,97]. Also, ERK1/2 has been reported to be
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overexpressed in patients with gastric cancer, this pathway represents an ideal target
for generating therapeutic drugs for patients with gastric cancer as discussed in many
articles [97,98].
In a study, they reported that when one signaling pathway is activated, it might
cause inhibition of other signaling pathways [38]. This concept is relatively new in
GPCR, and is referred to as biased GPCR signaling [99]. Since the activation of
different signaling pathways for PTH1R is studied, this shows that different activations
might depend on cell type, ligand, and condition of the cell [100]. For example a study
was conducted on HEK293 cells using a different PTH1R ligand, PTH (1-34) and was
reported to induce ERK1/2, but when they used a synthetic and modified ligand, PTH
(1-36) which solely acts on Gαs pathway, it failed to induce ERK1/2 and only activated
Gαs [42]. In PTH1R, biased agonism involving β-arrestin that acts independently from
GPCR mechanism is a new therapeutic target to improve osteoporosis therapy
[101,102].
Another result emerged at this point which is the presence of PTHLH in mGEP
cells as shown in Figure 3.2B. We proposed a hypothesis which states that as soon as
the mGEP cells are transfected with PTH1R, the cell will uptake its endogenous
PTHLH and activate the receptor. The prolonged overstimulation and exposure of
PTH1R to PTHLH will cause the receptor to reach its threshold and stop responding
to any further PTHLH or PTH treatment. As such the transfection is transient for a
time duration of 48 hrs, resulting in receptor desensitization and will thus activate
ERK1/2 pathway. The desensitization of GPCRs has been documented in other studies
as well which matches well with the proposed explanation above [38,42,103]. This
result was further confirmed when we transfected mGEP cells and noted cAMP
production without adding any treatment from our side, illustrated in Figure 3.7.
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However, whether or not the ligand PTHLH did internalize into the cell along with the
receptor, needs to be further examined since it was previously reported that PTHLH
contains an NLS as well [45].
Collectively, our results can be explained by receptor desensitization. In the
case of AGS cells, they do not express PTHLH as a ligand for PTH1R as reported in
one study [36], neither do they express the receptor PTH1R based on our finding
shown in Figure 3.1. Upon transfecting and treating the cells with PTHrP (1-36), the
receptor was activated causing an induction in Gαs pathway producing cAMP as shown
in Figure 3.6.
Using this proposed hypothesis, we can explain the results found in cell
viability as well, which resulted in inconsistent results as shown in Figure 3.9.
However, the morphological changes of transfected mGEP treated with different
concentrations of agonist and antagonist, as shown from Figure 3.10 showed larger
cell to cell spaces and longer connections between cells. This needs to be further
examined and investigated.
As for the target genes, no significant change was observed in CaSR, FGF23,
IL6 and NHERF1 between PTH1R-transfected mGEP and transfected and PTHrP (136) treated mGEP. This is also consistent with our previous findings in which we found
no significant change between transfected mGEP cells and transfected and treated
mGEP cells. Moreover, the significant change for the above mentioned target genes
were while comparing PTH1R-transfected mGEP with untransfected mGEP.
However, it is important to note that there was a significant upregulation of LDLR in
treated and PTH1R transfected mGEP in comparison with transfected mGEP.
Results showed a down regulation of CaSR, FGF23, IL-6 and NHERF1 in
transfected mGEP cells compared to untransfected mGEP cells. This can be explained
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in a negative feedback loop, in which it is supported by other studies [77], increased
calcium levels in the blood can be sensed by CaSR which will downregulate and inhibit
PTH1R from activating bone resorption to secrete more calcium in the blood. We
report a similar finding in which after 48 hrs of transfection, the negative feedback
loop for transfected mGEP cells caused the downregulation of the target genes in order
to maintain gastric calcium homeostasis as shown in Figure 3.18.
IL-6 and NHERF1 both showed a downregulation in PTH1R transfected mGEP
cells in comparison to untransfected mGEP cells. IL-6 is previously reported to be
upregulated by PTHLH in cancer patients [80]. NHERF1 is thought to inhibit PTH1R
desensitization [79,80]. My results could be explained as that in transfected mGEP
cells expressing PTH1R, NHERF1 is being used up by the cells in order to inhibit
PTH1R desensitization. This can be further illustrated in a slight increase in NHERF1
gene expression in transfected and PTHrP (1-36) treated mGEP cells.
LDLR showed a significant upregulation in PTH1R transfected and treated
mGEP cells in comparison to only PTH1R transfected cells. It is known from previous
research that PTH can induce LDLR [80]. LDLR is known to act via the Wnt signaling
pathway [104]. It has been also reported that PTH1R can act on the Wnt pathway along
with the frizzled GPCRs to regulate bone formation [105]. The Wnt pathway is a
pharmaceutical target to treat many different cancers [106]. Briefly, Wnt pathway
functions by activating either canonical or non-canonical pathway. In the case of noncanonical pathway, it is activated by LDLR and frizzled receptors. This will be
followed by a cascade of stimulations leading to activation of different Wnt target
genes which plays important roles in cellular regulation [106]. This shows that PTH1R
activation might suppress and downregulate other target genes in order to activate the
Wnt pathway, which is also reported in many gastric cancers [107]. The mechanism

66
of action and more details on this crosstalk which highlights the importance of
cholesterol and lipoprotein with PTH1R activation needs to be further investigated,
especially in the gastric system.
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5. Chapter 5: Conclusion and Future Directions

The present study aimed to determine the normal expression in vivo on mice
and the, function and role of PTH1R in gastric epithelium in vitro on mGEP (mouse)
and AGS (human) cells. These aims were established by further studying the signaling
pathway of PTH1R and the mechanism of induction in the gastric epithelial cells.
Overall findings are shown in figure 5.1.
Our in vivo results showed positive expression of PTH1R on both
transcriptional and translational levels in the forestomach, corpus, and antrum of the
gastric epithelium of wild type mice. Another important in vivo result was the
expression of PTH1R in normal human stomach.
Our in vitro results were subdivided into two, where we tested the signaling
pathway of AGS and mGEP mouse cell lines. In the case of AGS, cAMP was induced
in PTH1R transfected and PTHrP (1-36) treated cells. mGEP cells, on the other hand,
showed expression of the ligand PTHLH, and PTH1R transfected and PTHrP (1-36)
treated mGEP cells did not induce cAMP, in fact pERK1/2 was reported which is
highly linked to receptor desensitization.
Target genes were also investigated in this study, and while comparing
untransfected mGEP cells to transfected mGEP cells, significant downregulation was
reported in CaSR, FGF23, IL6, and NHERF1. On the other hand, upregulation of
LDLR in PTH1R transfected and treated mGEP cells in comparison with transfected
mGEP. Collectively, these results showed the importance of PTH1R in maintaining
and regulating gastric epithelium.
PTH1R is not highly studied in the gastric glands. One of our interesting results
is the expression of PTH1R in normal mouse stomach. However, the exact localization
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of the receptor needs to be further investigated by conducting immune co-staining of
different types of gastric cells and PTH1R. Especially, since previous findings
illustrate cAMP importance in regulating parietal cells to secrete gastric acid. It will
be novel to identify the exact location of PTH1R and whether or not it is expressed in
parietal cells, since these cells also express PTHLH. This might propose a functional
mechanism to identify PTHLH autocrine regulatory role in maintaining gastric
homeostasis.
PTH1R is a GPCR which was identified with NLS in the C terminal as
previously reported; however, no further research examined how this sequence
functions in the stomach and its role in comparison to normal receptor activation.
Investigating this issue by creating a PTH1R C terminal knock out might highlight
new modified signaling mechanism in response to specific ligand-binding sites.
Moreover, PTHLH contains NLS as well, it would be interesting to examine by coprecipitation if PTHLH will internalize with PTH1R in any specific signaling system.
Our morphological study showed difference between transfected mGEP and
untransfected mGEP cells. A future study aiming the use of electron microscopy to
detect the changes inside the cell will be beneficial in understanding the morphological
changes.
In this study, the only two pathways studied were Gαs and ERK1/2. It is vital
to study the other signaling pathways as the receptor can act otherwise in different
organs and systems using different agonists. Also, one of the aims in future directions
could be testing the phosphorylation of ERK1/2 using western blot at different time
points after treating the cells with PTHrP (1-36). In this study, PTHrP (1-36) agonist
was used to stimulate PTH1R, however, other agonists exist such as PTH (1-34), and
it would be interesting to examine it for similar or different results.
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Since the focus of this project was on PTH1R in the gastric gland, very little
studies were available to compare our results to. More research needs to be conducted
on gastric cancer and the signaling pathway that is activated when PTH1R expression
is upregulated.
To overcome the endogenous PTHLH effect on cells and its alteration of the
results, it will be a better option to use AGS transfected cells since it does not express
PTHLH, this will lead to more consistent results.
The target genes investigated in this thesis were CaSR, FGF23, IL6, LDLR,
and NHERF1 by Real-Time PCR. It is important to investigate more target genes in
the future to be able to examine the overall change in the gastric system. For this
project, only 0.1 µM which is a small concentration of PTHrP (1-36) was used in
treating transfected mGEP cells for five minutes only. Other concentrations and
different times should be further studied. Creating a detailed time and dose study to
confirm the hypothesis of desensitization in the RT-PCR experiment will be helpful.
Also, treating the transfected mGEP cells with an antagonist PTHrP (7-34) should
restore the gene expression of the target genes.
Finally, PTH1R in vitro study on gastric cell lines showed change and
induction of several signaling pathways and target genes. Conducting further studies
on the importance of PTH1R in gastric glands in vivo would be very interesting, either
by knockdown of PTH1R, or treating wild type mice of different ages with PTH1R
agonists and antagonists for different times and concentrations.
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Figure 5.1: Conclusive overall result model illustrating final findings

71
6. References

[1] A. Izquierdo et al., “The parathyroid hormone-related protein system and
diabetic nephropathy outcome in streptozotocin-induced diabetes,” Kidney Int.
Lond., vol. 69, no. 12, pp. 2171–2177, 2006.
[2] M. Mannstadt, H. Jüppner, and T. J. Gardella, “Receptors for PTH and PTHrP:
their biological importance and functional properties,” Am. J. Physiol.-Ren.
Physiol., vol. 277, no. 5, pp. F665–F675, 1999.
[3] T. L. Clemens et al., “Parathyroid hormone-related protein and its receptors:
nuclear functions and roles in the renal and cardiovascular systems, the placental
trophoblasts and the pancreatic islets,” Br. J. Pharmacol., vol. 134, no. 6, pp.
1113–1136, 2001.
[4] R. C. Gensure, T. J. Gardella, and H. Jüppner, “Parathyroid hormone and
parathyroid hormone-related peptide, and their receptors,” Biochem. Biophys.
Res. Commun., vol. 328, no. 3, pp. 666–678, 2005.
[5] D. Zindel et al., “Identification of key phosphorylation sites in PTH1R that
determine arrestin3 binding and fine-tune receptor signaling,” Biochem. J., vol.
473, no. 22, pp. 4173–4192, 2016.
[6] J.-P. Vilardaga, G. Romero, P. A. Friedman, and T. J. Gardella, “Molecular basis
of parathyroid hormone receptor signaling and trafficking: a family B GPCR
paradigm,” Cell. Mol. Life Sci. CMLS, vol. 68, no. 1, pp. 1–13, 2011.
[7] M. Ito, M. Nakashima, T. Nakayama, S. Shikuwa, A. Ohtsuru, and I. Sekine,
“Preventive effects of parathyroid hormone-related peptide on stress-induced
gastric hypercontraction in the rat,” J. Gastroenterol. Hepatol., vol. 17, no. 12,
pp. 1260–1266, 2002.
[8] W. Chang et al., “Parathyroid Hormone-Like Hormone is a Poor Prognosis
Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2
Regulation,” Sci. Rep. Nat. Publ. Group Lond., vol. 7, pp. 41131-41143, 2017.
[9] M. Nakashima et al., “Expression of parathyroid hormone-related peptide in
human thyroid tumours,” J. Pathol., vol. 175, no. 2, pp. 227–236, 1995.
[10] W. Hoffmann, “Stem Cells, Self-Renewal and Cancer of the Gastric
Epithelium,” Current Medicinal Chemistry, 30-Nov-2012. [Online]. Available:
http://www.eurekaselect.com/105285/article. [Accessed: 16-Mar-2019].
[11] S. M. Karam, “Lineage commitment and maturation of epithelial cells in the
gut,” Front. Biosci. J. Virtual Libr., vol. 4, pp. D286-298, 1999.

72
[12] Z. Cheng, D. Garvin, A. Paguio, P. Stecha, K. Wood, and F. Fan, “Luciferase
Reporter Assay System for Deciphering GPCR Pathways,” Curr. Chem.
Genomics, vol. 4, pp. 84–91, 2010.
[13] W. N. Dare, C. A. Oyinbo, and A.-H. M. Izunya, “Study of the Structure of the
Gastric Mucosa in the Mouse (Cell Population),” J. Life Sci. Biomed., vol. 2, no.
5, pp 182-186, 2012.
[14] S. M. Karam and C. P. Leblond, “Identifying and counting epithelial cell types
in the ‘corpus’ of the mouse stomach,” Anat. Rec., vol. 232, no. 2, pp. 231–246,
1992.
[15] S. M. Karam, “Dynamics of epithelial cells in the corpus of the mouse stomach.
IV. Bidirectional migration of parietal cells ending in their gradual degeneration
and loss,” Anat. Rec., vol. 236, no. 2, pp. 314–332, 1993.
[16] G.-M. Hu, T.-L. Mai, and C.-M. Chen, “Visualizing the GPCR Network:
Classification and Evolution,” Sci. Rep., vol. 7, no. 1, pp. 15495–15510, 2017.
[17] V. V. Gurevich and E. V. Gurevich, “Molecular Mechanisms of GPCR
Signaling: A Structural Perspective,” Int. J. Mol. Sci., vol. 18, no. 12, pp. 2519–
2536, 2017.
[18] X. Cong, J. Topin, and J. Golebiowski, “Class A GPCRs: Structure, Function,
Modeling and Structure-based Ligand Design,” Curr. Pharm. Des., vol. 23, no.
29, pp. 4390–4409, 2017.
[19] A. Bortolato, A. S. Doré, K. Hollenstein, B. G. Tehan, J. S. Mason, and F. H.
Marshall, “Structure of Class B GPCRs: new horizons for drug discovery,” Br. J.
Pharmacol., vol. 171, no. 13, pp. 3132–3145, 2014.
[20] L. Chun, W. Zhang, and J. Liu, “Structure and ligand recognition of class C
GPCRs,” Acta Pharmacol. Sin., vol. 33, no. 3, pp. 312–323, 2012.
[21] M. Eilers, V. Hornak, S. O. Smith, and J. B. Konopka, “Comparison of Class A
and D G Protein-Coupled Receptors: Common Features in Structure and
Activation,” Biochemistry, vol. 44, no. 25, pp. 8959–8975, 2005.
[22] P. S. Klein, T. J. Sun, C. L. Saxe, A. R. Kimmel, R. L. Johnson, and P. N.
Devreotes, “A chemoattractant receptor controls development in Dictyostelium
discoideum,” Science, vol. 241, no. 4872, pp. 1467–1472, 1988.
[23] R. L. Johnson, C. L. Saxe, R. Gollop, A. R. Kimmel, and P. N. Devreotes,
“Identification and targeted gene disruption of cAR3, a cAMP receptor subtype
expressed during multicellular stages of Dictyostelium development.,” Genes
Dev., vol. 7, no. 2, pp. 273–282, 1993.
[24] H.-C. Huang and P. S. Klein, “The Frizzled family: receptors for multiple signal
transduction pathways,” Genome Biol., vol. 5, no. 7, pp. 234–241, 2004.

73
[25] C. Wang et al., “Structural basis for Smoothened receptor modulation and
chemoresistance to anticancer drugs,” Nat. Commun., vol. 5, pp. 4355–4375,
2014.
[26] H. Juppner, M. Freeman, and et al, “A G Protein-Linked Receptor for
Parathyroid Hormone and Parathyroid Hormone-Related Peptide,” Sci. Wash.,
vol. 254, no. 5034, pp. 1024–1026, 1991.
[27] H. Subramanian et al., “PTH1R Mutants Found in Patients with Primary Failure
of Tooth Eruption Disrupt G-Protein Signaling,” PLoS ONE, vol. 11, no. 11,
2016.
[28] T. J. Martin, “Parathyroid Hormone-Related Protein, Its Regulation of Cartilage
and Bone Development, and Role in Treating Bone Diseases,” Physiol. Rev., vol.
96, no. 3, pp. 831–871, 2016.
[29] T. J. Gardella and J.-P. Vilardaga, “International Union of Basic and Clinical
Pharmacology. XCIII. The Parathyroid Hormone Receptors—Family B G
Protein–Coupled Receptors,” Pharmacol. Rev., vol. 67, no. 2, pp. 310–337,
2015.
[30] E. K. Patterson et al., “Expression of PTH1R constructs in LLC-PK1 cells:
Protein nuclear targeting is mediated by the PTH1R NLS,” Bone, vol. 41, no. 4,
pp. 603–610, 2007.
[31] B. W. Pickard, A. B. Hodsman, L. J. Fraher, and P. H. Watson, “Type 1
Parathyroid Hormone Receptor (PTH1R) Nuclear Trafficking: Regulation of
PTH1R Nuclear-Cytoplasmic Shuttling by Importin-α/β and Chromosomal
Region Maintenance 1/Exportin 1,” Endocrinology, vol. 148, no. 5, pp. 2282–
2289, 2007.
[32] J. S. Martins, M. de O. Palhares, O. C. M. Teixeira, and M. Gontijo Ramos,
“Vitamin D Status and Its Association with Parathyroid Hormone Concentration
in Brazilians,” J. Nutr. Metab., vol. 2017, 2017.
[33] D. Nikitovic et al., “Parathyroid hormone/parathyroid hormone-related peptide
regulate osteosarcoma cell functions: Focus on the extracellular matrix
(Review),” Oncol. Rep., vol. 36, no. 4, pp. 1787–1792, 2016.
[34] G. J. Strewler, R. D. Williams, and R. A. Nissenson, “Human renal carcinoma
cells produce hypercalcemia in the nude mouse and a novel protein recognized
by parathyroid hormone receptors.,” J. Clin. Invest., vol. 71, no. 3, pp. 769–774,
1983.
[35] A. H. Tashjian, L. Levine, and P. L. Munson, “IMMUNOCHEMICAL
IDENTIFICATION OF PARATHYROID HORMONE IN NONPARATHYROID NEOPLASMS ASSOCIATED WITH HYPERCALCEMIA,”
J. Exp. Med., vol. 119, no. 3, pp. 467–484, 1964.

74
[36] A. Al Menhali, T. M. Keeley, E. S. Demitrack, and L. C. Samuelson, “Gastrin
induces parathyroid hormone-like hormone expression in gastric parietal cells,”
Am. J. Physiol. - Gastrointest. Liver Physiol., vol. 312, no. 6, pp. G649–G657,
2017.
[37] J. C. Mills, A. J. Syder, C. V. Hong, J. L. Guruge, F. Raaii, and J. I. Gordon, “A
molecular profile of the mouse gastric parietal cell with and without exposure to
Helicobacter pylori,” Proc. Natl. Acad. Sci. U. S. A., vol. 98, no. 24, pp. 13687–
13692, 2001.
[38] W. B. Sneddon et al., “Ligand-Selective Dissociation of Activation and
Internalization of the Parathyroid Hormone (PTH) Receptor: Conditional
Efficacy of PTH Peptide Fragments,” Endocrinology, vol. 145, no. 6, pp. 2815–
2823, 2004.
[39] N. Sahoo et al., “Gastric acid secretion from parietal cells is mediated by a Ca2+
efflux channel in the tubulovesicle,” Dev. Cell, vol. 41, no. 3, pp. 262-273.e6,
2017.
[40] Z.-Q. Li and S. Mårdh, “Interactions between Ca2+- and cAMP-dependent
stimulatory pathways in parietal cells,” Biochim. Biophys. Acta BBA - Mol. Cell
Res., vol. 1311, no. 2, pp. 133–142, 1996.
[41] C. S. Chew, “Parietal cell protein kinases. Selective activation of type I cAMPdependent protein kinase by histamine.,” J. Biol. Chem., vol. 260, no. 12, pp.
7540–7550, 1985.
[42] C. A. Syme, P. A. Friedman, and A. Bisello, “Parathyroid Hormone Receptor
Trafficking Contributes to the Activation of Extracellular Signal-regulated
Kinases but Is Not Required for Regulation of cAMP Signaling,” J. Biol. Chem.,
vol. 280, no. 12, pp. 11281–11288, 2005.
[43] Y. Pazos, C. J. P. Alvarez, J. P. Camiña, and F. F. Casanueva, “Stimulation of
extracellular signal-regulated kinases and proliferation in the human gastric
cancer cells KATO-III by obestatin,” Growth Factors, vol. 25, no. 6, pp. 373–
381, 2007.
[44] W. Yan, S. Chen, Y. Zhao, and X. Ye, “Fisetin inhibits the proliferation of
gastric cancer cells and induces apoptosis through suppression of ERK 1/2
activation,” Oncol. Lett., vol. 15, no. 6, pp. 8442–8446, 2018.
[45] M. M. Aarts, A. Rix, J. Guo, R. Bringhurst, and J. E. Henderson, “The nucleolar
targeting signal (NTS) of parathyroid hormone related protein mediates
endocytosis and nucleolar translocation,” J. Bone Miner. Res. Off. J. Am. Soc.
Bone Miner. Res., vol. 14, no. 9, pp. 1493–1503, 1999.

75
[46] S. L. Ritter and R. A. Hall, “Fine-tuning of GPCR activity by receptorinteracting proteins,” Nat. Rev. Mol. Cell Biol., vol. 10, no. 12, pp. 819–830,
2009.
[47] O. Calvete, M. Herraiz, J. Reyes, A. Patiño, and J. Benitez, “A cumulative effect
involving malfunction of the PTH1R and ATP4A genes explains a familial
gastric neuroendocrine tumor with hypothyroidism and arthritis,” Gastric
Cancer, vol. 20, no. 6, pp. 998–1003, 2017.
[48] I. M. al et, “Gastric cancer associated with overexpression of parathyroid
hormone-related peptide (PTHrP) and PTH/PTHrP receptor in relation to tumor
progression. - PubMed - NCBI.” [Online]. Available:
https://www.ncbi.nlm.nih.gov/pubmed/9213256. [Accessed: 16-Apr-2019].
[49] I. M. and O. A, “[Parathyroid hormone-related peptide (PTHrP) and
PTH/PTHrP receptor in the gastrointestinal tract]. - PubMed - NCBI.” [Online].
Available: https://www.ncbi.nlm.nih.gov/pubmed/8920682. [Accessed: 16-Apr2019].
[50] P. W. M. Ho et al., “Knockdown of PTHR1 in osteosarcoma cells decreases
invasion and growth and increases tumor differentiation in vivo,” Oncogene N.
Y., vol. 34, no. 22, pp. 2922–2933, 2015.
[51] K. Motomura et al., “Osteogenic action of parathyroid hormone-related peptide
(1-141) in rat ROS cells.,” Endocr. J., vol. 43, no. 5, pp. 527–535, 1996.
[52] M. J. Horwitz, M. B. Tedesco, C. Gundberg, A. Garcia-Ocana, and A. F.
Stewart, “Short-Term, High-Dose Parathyroid Hormone-Related Protein as a
Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis,” J.
Clin. Endocrinol. Metab., vol. 88, no. 2, pp. 569–575, 2003.
[53] J. L. Vahle et al., “Skeletal Changes in Rats Given Daily Subcutaneous
Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and
Relevance to Human Safety,” Toxicol. Pathol., vol. 30, no. 3, pp. 312–321, 2002.
[54] M. Maycas, J. A. Ardura, L. F. de Castro, B. Bravo, A. R. Gortázar, and P.
Esbrit, “Role of the Parathyroid Hormone Type 1 Receptor (PTH1R) as a
Mechanosensor in Osteocyte Survival,” J. Bone Miner. Res., vol. 30, no. 7, pp.
1231–1244, 2015.
[55] D. Yang, R. Singh, P. Divieti, J. Guo, M. L. Bouxsein, and F. R. Bringhurst,
“Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor
signaling pathways to the anabolic effect of PTH on bone,” Bone, vol. 40, no. 6,
pp. 1453–1461, 2007.
[56] R. L. Jilka, “Molecular and cellular mechanisms of the anabolic effect of
intermittent PTH,” Bone, vol. 40, no. 6, pp. 1434–1446, 2007.

76
[57] J. Feng et al., “A novel human parathyroid hormone (1-34) analog for the
treatment of osteoporosis,” Peptides, vol. 30, no. 6, pp. 1173–1180, 2009.
[58] Y. Yang and B. Wang, “PTH1R-CaSR Cross Talk: New Treatment Options for
Breast Cancer Osteolytic Bone Metastases,” International Journal of
Endocrinology, 2018. [Online]. Available:
https://www.hindawi.com/journals/ije/2018/7120979/. [Accessed: 25-Feb-2019].
[59] N. J. Bundred, W. A. Ratcliffe, R. A. Walker, S. Coley, J. M. Morrison, and J.
G. Ratcliffe, “Parathyroid hormone related protein and hypercalcaemia in breast
cancer.,” BMJ, vol. 303, no. 6816, pp. 1506–1509, 1991.
[60] A. Dittmer et al., “Parathyroid Hormone-related Protein Regulates Tumorrelevant Genes in Breast Cancer Cells,” J. Biol. Chem., vol. 281, no. 21, pp.
14563–14572, 2006.
[61] H. Liang, Y. Zhong, Y. Huang, and G. Chen, “Type 1 receptor parathyroid
hormone (PTH1R) influences breast cancer cell proliferation and apoptosis
induced by high levels of glucose,” Med. Oncol., vol. 29, no. 2, pp. 439–445,
2012.
[62] K. Aya, H. Tanaka, Y. Ichinose, M. Kobayashi, and Y. Seino, “Expression of
parathyroid hormone-related peptide messenger ribonucleic acid in developing
kidney,” Kidney Int., vol. 55, no. 5, pp. 1696–1703, 1999.
[63] N. Amizuka et al., “Cell-Specific Expression of the Parathyroid Hormone
(PTH)/PTH-Related Peptide Receptor Gene in Kidney from Kidney-Specific and
Ubiquitous Promoters,” Endocrinology, vol. 138, no. 1, pp. 469–481, 1997.
[64] M. Müller, S. Gagiannis, P. P. Nawroth, M. Brune, and T. Schilling, “Activation
of the receptor for parathyroid hormone and parathyroid hormone related protein
induces apoptosis via the extrinsic and intrinsic signaling pathway,” Int. J. Mol.
Med., vol. 24, no. 3, pp. 373–380, 2009.
[65] M. Romero et al., “Novel Role of Parathyroid Hormone-Related Protein in the
Pathophysiology of the Diabetic Kidney: Evidence from Experimental and
Human Diabetic Nephropathy,” Journal of Diabetes Research, 2013. [Online].
Available: https://www.hindawi.com/journals/jdr/2013/162846/. [Accessed: 20Mar-2019].
[66] J. Shimomura-Kuroki, M. Farooq, T. Sekimoto, N. Amizuka, and Y.
Shimomura, “Characterization of a PTH1R missense mutation responsible for
Jansen type metaphyseal chondrodysplasia,” Odontology, vol. 105, no. 2, pp.
150–154, 2017.
[67] S. Nampoothiri et al., “Jansen Metaphyseal Chondrodysplasia due to
Heterozygous H223R-PTH1R Mutations With or Without Overt
Hypercalcemia,” J. Clin. Endocrinol. Metab., vol. 101, no. 11, pp. 4283–4289,
2016.

77
[68] E. Decker et al., “PTHR1 loss-of-function mutations in familial, nonsyndromic
primary failure of tooth eruption,” Am. J. Hum. Genet., vol. 83, no. 6, pp. 781–
786, 2008.
[69] S. Duchatelet, E. Ostergaard, D. Cortes, A. Lemainque, and C. Julier,
“Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken
and Blomstrand syndromes,” Hum. Mol. Genet., vol. 14, no. 1, pp. 1–5, 2005.
[70] M. Bastepe et al., “A form of Jansen’s metaphyseal chondrodysplasia with
limited metabolic and skeletal abnormalities is caused by a novel activating
parathyroid hormone (PTH)/PTH-related peptide receptor mutation,” J. Clin.
Endocrinol. Metab., vol. 89, no. 7, pp. 3595–3600, 2004.
[71] F. M. Hannan, V. N. Babinsky, and R. V. Thakker, “Disorders of the calciumsensing receptor and partner proteins: insights into the molecular basis of
calcium homeostasis,” J. Mol. Endocrinol., vol. 57, no. 3, pp. R127–R142, 2016.
[72] C. M. Gorvin, “Insights into calcium-sensing receptor trafficking and biased
signalling by studies of calcium homeostasis,” J. Mol. Endocrinol., vol. 61, no. 1,
pp. R1–R12, 2018.
[73] C. S. Maria et al., “Interplay between CaSR and PTH1R Signaling in Skeletal
Development and Osteoanabolism,” Semin. Cell Dev. Biol., vol. 49, pp. 11–23,
2016.
[74] Y. Xue et al., “The calcium-sensing receptor complements parathyroid
hormone-induced bone turnover in discrete skeletal compartments in mice,” Am.
J. Physiol. - Endocrinol. Metab., vol. 302, no. 7, pp. E841–E851, 2012.
[75] W. Kim et al., “Calcium-Sensing Receptor (CaSR) Promotes Breast Cancer by
Stimulating Intracrine Actions of Parathyroid Hormone-Related Protein,” Cancer
Res., vol. 76, no. 18, pp. 5348–5360, 2016.
[76] M. M. Dufner et al., “The calcium-sensing receptor acts as a modulator of
gastric acid secretion in freshly isolated human gastric glands,” Am. J. Physiol.Gastrointest. Liver Physiol., vol. 289, no. 6, pp. G1084–G1090, 2005.
[77] R. Xie et al., “Calcium Promotes Human Gastric Cancer via a Novel Coupling
of Calcium-Sensing Receptor and TRPV4 Channel,” Cancer Res., vol. 77, no.
23, pp. 6499–6512, 2017.
[78] I. Kaneko, R. K. Saini, K. P. Griffin, G. K. Whitfield, M. R. Haussler, and P. W.
Jurutka, “FGF23 gene regulation by 1,25-dihydroxyvitamin D: Opposing effects
in adipocytes and osteocytes,” J. Endocrinol., vol. 226, no. 3, pp. 155–166, 2015.
[79] V. Lavi-Moshayoff, G. Wasserman, T. Meir, J. Silver, and T. Naveh-Many,
“PTH increases FGF23 gene expression and mediates the high-FGF23 levels of

78
experimental kidney failure: a bone parathyroid feedback loop,” Am. J. Physiol.Ren. Physiol., vol. 299, no. 4, pp. F882–F889, 2010.
[80] V. M. Knab et al., “Acute Parathyroid Hormone Injection Increases C-Terminal
but Not Intact Fibroblast Growth Factor 23 Levels,” Endocrinology, vol. 158, no.
5, pp. 1130–1139, 2017.
[81] N. Ide et al., “In vivo evidence for an interplay of FGF23/Klotho/PTH axis on
the phosphate handling in renal proximal tubules,” Am. J. Physiol.-Ren. Physiol.,
vol. 315, no. 5, pp. F1261–F1270, 2018.
[82] Y. Fan et al., “Parathyroid hormone 1 receptor is essential to induce FGF23
production and maintain systemic mineral ion homeostasis,” FASEB J., vol. 30,
no. 1, pp. 428–440, 2016.
[83] S. Takahashi et al., “Elevation of circulating plasma cytokines in cancer patients
with high plasma parathyroid hormone-related protein levels,” Endocr. Relat.
Cancer, vol. 10, no. 3, pp. 403–407, 2003.
[84] T. Ashizawa et al., “Clinical significance of interleukin-6 (IL-6) in the spread of
gastric cancer: role of IL-6 as a prognostic factor,” Gastric Cancer, vol. 8, no. 2,
pp. 124–131, 2005.
[85] M. Ikeguchi et al., “Serum interleukin-6 and -10 levels in patients with gastric
cancer,” Gastric Cancer, vol. 12, no. 2, pp. 95–100, 2009.
[86] A. ValÍn, C. Guillén, and P. Esbrit, “C-Terminal Parathyroid Hormone-Related
Protein (PTHrP) (107–139) Stimulates Intracellular Ca2+ through a Receptor
Different from the Type 1 PTH/PTHrP Receptor in Osteoblastic Osteosarcoma
UMR 106 Cells,” Endocrinology, vol. 142, no. 7, pp. 2752–2759, 2001.
[87] N. S. Datta and A. B. Abou-Samra, “PTH and PTHrP signaling in osteoblasts,”
Cell. Signal., vol. 21, no. 8, pp. 1245–1254, Aug. 2009.
[88] M. Wan et al., “Parathyroid hormone signaling through low-density lipoproteinrelated protein 6,” Genes Dev., vol. 22, no. 21, pp. 2968–2979, 2008.
[89] D. Wheeler, J. L. Garrido, A. Bisello, Y. K. Kim, P. A. Friedman, and G.
Romero, “Regulation of Parathyroid Hormone Type 1 Receptor Dynamics,
Traffic, and Signaling by the Na+/H+ Exchanger Regulatory Factor-1 in Rat
Osteosarcoma ROS 17/2.8 Cells,” Mol. Endocrinol., vol. 22, no. 5, pp. 1163–
1170, 2008.
[90] A. Mangia et al., “The potential predictive role of nuclear NHERF1 expression
in advanced gastric cancer patients treated with
epirubicin/oxaliplatin/capecitabine first line chemotherapy,” Cancer Biol. Ther.,
vol. 16, no. 8, pp. 1140–1147, 2015.

79
[91] M. Centonze, C. Saponaro, and A. Mangia, “NHERF1 Between Promises and
Hopes: Overview on Cancer and Prospective Openings,” Transl. Oncol., vol. 11,
no. 2, pp. 374–390, 2018.
[92] G. Du et al., “The cellular distribution of Na+/H+ exchanger regulatory factor 1
is determined by the PDZ-I domain and regulates the malignant progression of
breast cancer,” Oncotarget, vol. 7, no. 20, pp. 29440–29453, 2016.
[93] W. B. Sneddon et al., “Activation-independent parathyroid hormone receptor
internalization is regulated by NHERF1 (EBP50),” J. Biol. Chem., vol. 278, no.
44, pp. 43787–43796, 2003.
[94] B. Wang, Y. Yang, A. B. Abou-Samra, and P. A. Friedman, “NHERF1
Regulates Parathyroid Hormone Receptor Desensitization: Interference with βArrestin Binding,” Mol. Pharmacol., vol. 75, no. 5, pp. 1189–1197, 2009.
[95] M. J. Mahon, “The parathyroid hormone 1 receptor directly binds to the FERM
domain of ezrin, an interaction that supports apical receptor localization and
signaling in LLC-PK1 cells,” Mol. Endocrinol. Baltim. Md, vol. 23, no. 10, pp.
1691–1701, 2009.
[96] V. S. Farook, M. Alkhalaf, and S. M. Karam, “Establishment of a gastric
epithelial progenitor cell line from a transgenic mouse expressing the simian
virus 40 large T antigen gene in the parietal cell lineage,” Cell Prolif., vol. 41,
no. 2, pp. 310–320, 2008.
[97] Y. Fujimori, M. Inokuchi, Y. Takagi, K. Kato, K. Kojima, and K. Sugihara,
“Prognostic value of RKIP and p-ERK in gastric cancer,” J. Exp. Clin. Cancer
Res., vol. 31, no. 1, pp. 30–38, 2012.
[98] E. Ihara, H. Akiho, K. Nakamura, S. R. Turner, and J. A. Macdonald, “MAPKs
represent novel therapeutic targets for gastrointestinal motility disorders,” World
J. Gastrointest. Pathophysiol., vol. 2, no. 2, pp. 19–25, 2011.
[99] A. K. Shukla, G. Singh, and E. Ghosh, “Emerging structural insights into biased
GPCR signaling,” Trends Biochem. Sci., vol. 39, no. 12, pp. 594–602, 2014.
[100] D. Gesty-Palmer and L. M. Luttrell, “‘Biasing’ the parathyroid hormone
receptor: a novel anabolic approach to increasing bone mass?,” Br. J.
Pharmacol., vol. 164, no. 1, pp. 59–67, 2011.
[101] B. N. Bohinc and D. Gesty-Palmer, “Biased agonism at the parathyroid
hormone receptor: a demonstration of functional selectivity in bone metabolism,”
Mini Rev. Med. Chem., vol. 12, no. 9, pp. 856–865, 2012.
[102] K. M. Appleton et al., “Biasing the parathyroid hormone receptor: relating in
vitro ligand efficacy to in vivo biological activity,” Methods Enzymol., vol. 522,
pp. 229–262, 2013.

80
[103] S. Rajagopal and S. K. Shenoy, “GPCR desensitization: Acute and prolonged
phases,” Cell. Signal., vol. 41, pp. 9–16, 2018.
[104] M. A. Chiurillo, “Role of the Wnt/β-catenin pathway in gastric cancer: An indepth literature review,” World J. Exp. Med., vol. 5, no. 2, pp. 84–102, 2015.
[105] G. Romero, W. B. Sneddon, Y. Yang, D. Wheeler, H. C. Blair, and P. A.
Friedman, “Parathyroid Hormone Receptor Directly Interacts with Dishevelled to
Regulate β-Catenin Signaling and Osteoclastogenesis,” J. Biol. Chem., vol. 285,
no. 19, pp. 14756–14763, 2010.
[106] N. Krishnamurthy and R. Kurzrock, “Targeting the Wnt/beta-catenin Pathway
in Cancer: Update on Effectors and Inhibitors,” Cancer Treat. Rev., vol. 62, pp.
50–60, 2018.
[107] J. Mao et al., “Roles of Wnt/β-catenin signaling in the gastric cancer stem cells
proliferation and salinomycin treatment,” Cell Death Dis., vol. 5, no. 1, pp.
e1039, 2014.

Digitally signed by
Shrieen
DN: cn=Shrieen,
o=United Arab Emirates
University, ou=UAEU
Library Digitizatio,
email=shrieen@uaeu.ac.
ae, c=AE
Date: 2021.08.02
08:45:33 +04'00'

